Author: "Netherlands Institute for Health Services Research" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Netherlands Institute for Health Services Research"' showing total 1,850 results

Start Over Author "Netherlands Institute for Health Services Research"

1,850 results on '"Netherlands Institute for Health Services Research"'

1. Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer (NABOR)

Author: University of Twente, Dutch Breast Cancer Association, Borstkanker Onderzoek Groep, Netherlands Institute for Health Services Research, and Sabine Siesling, Senior researcher, full professor
Published: 2023

2. Preparing for the upcoming 2022/23 influenza season: a modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom

Author: Bronke Boudewijns, John Paget, Marco Del Riccio, Laurent Coudeville, Pascal Crépey, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), Recherche sur les services et le management en santé (RSMS), and Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Pulmonary and Respiratory Medicine, Europe, Infectious Diseases, Epidemiology, Susceptibility, Public Health, Environmental and Occupational Health, Australia, COVID-19, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Influenza, Modelling
Abstract: Online ahead of print.; International audience; We analysed the influenza epidemic that occurred in Australia during the 2022 winter using an age-structured dynamic transmission model, which accounts for past epidemics to estimate the population susceptibility to an influenza infection. We applied the same model to five European countries. Our analysis suggests Europe might experience an early and moderately large influenza epidemic. Also, differences may arise between countries, with Germany and Spain experiencing larger epidemics, than France, Italy and the United Kingdom, especially in children.
Published: 2022

3. Vulnerability and One Health assessment approaches for infectious threats from a social science perspective: a systematic scoping review

Author: Maren Jeleff, Lisa Lehner, Tamara Giles-Vernick, Michel L A Dückers, A David Napier, Elena Jirovsky-Platter, Ruth Kutalek, Medizinische Universität Wien = Medical University of Vienna, Anthropologie et écologie de l’émergence des maladies - Anthropology and Ecology of Disease Emergence, Institut Pasteur [Paris] (IP), Netherlands Institute for Health Services Research [Utrecht] (NIVEL), University of Groningen [Groningen], University College of London [London] (UCL), We thank the EU's Horizon 2020 research and innovation programme (grant agreement number: 825671) for funding this research., and European Project: 825671,H2020-SC1-2018-Single-Stage-RTD ,SoNAR-Global(2019)
Subjects: Health (social science), Health Policy, Climate Change, Public Health, Environmental and Occupational Health, Medicine (miscellaneous), Humans, Social Sciences, One Health, Environment, Communicable Diseases, [SHS]Humanities and Social Sciences
Abstract: International audience; Vulnerability assessments identify vulnerable groups and can promote effective community engagement in responding to and mitigating destabilising events. This scoping review maps assessments for local-level vulnerabilities in the context of infectious threats. We searched various databases for articles written between 1978 and 2019. Eligible documents assessed local-level vulnerability, focusing on infectious threats and antimicrobial resistance. Since few studies provided this dual focus, we included tools from climate change and disaster risk reduction literature that engaged the community in the assessment. We considered studies using a One Health approach as essential for identifying vulnerability risk factors for zoonotic disease affecting humans. Of the 5390 records, we selected 36 articles for review. This scoping review fills a gap regarding vulnerability assessments by combining insights from various approaches: local-level understandings of vulnerability involving community perspectives; studies of social and ecological factors relevant to exposure; and integrated quantitative and qualitative methods that make generalisations based on direct observation. The findings inform the development of new tools to identify vulnerabilities and their relation to social and natural environments.
Published: 2022

4. Noise sensitivity: Symptoms, health status, illness behavior and co-occurring environmental sensitivities

Author: Yzermans, Joris [Netherlands Institute for Health Services Research (NIVEL), Utrecht (Netherlands)]
Published: 2016
Full Text: View/download PDF

5. Project Report on Delphi process on best practice of health care for Immigrants : European Best Practices in Access, Quality and Appropriateness of Health Services for Immigrants in Europe

Author: DeVillé , Walter, Lamkaddem , Majda, Dauvrin, Marie, Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands - Netherlands Institute for Health Services Research, and UCL - SSS/IRSS - Institut de recherche santé et société
Subjects: RA0421
Published: 2011

6. Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned

Author: Bagaria, Jayshree, Jansen, Tessa, Marques, Diogo Fp, Hooiveld, Mariette, McMenamin, Jim, de Lusignan, Simon, Vilcu, Ana-Maria, Meijer, Adam, Rodrigues, Ana-Paula, Brytting, Mia, Mazagatos, Clara, Cogdale, Jade, van der Werf, Sylvie, Dijkstra, Frederika, Guiomar, Raquel, Enkirch, Theresa, Valenciano, Marta, I-MOVE-COVID-19 study team, Larrauri, Amparo, Pozo Sanchez, Francisco, Casas Flecha, Inmaculada, Unión Europea. Comisión Europea. H2020, Public Health Scotland [Glasgow], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), EpiConcept [Paris], University of Oxford, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Institute of Health Carlos III, UK Health Security Agency (UKHSA), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O'Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela Mc Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass, European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), HAL-SU, Gestionnaire, Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic - I-MOVE-COVID-19 - - H2020-SC1-PHE-CORONAVIRUS-20202020-03-16 - 2022-06-15 - 101003673 - VALID, UK Health Security Agency [London] (UKHSA), and Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur)
Subjects: Epidemiology, Sentinel surveillance, primary care, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Influenza, Human, Humans, Influenza-Like Illness, Pandemics, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Primary Health Care, SARS-CoV-2, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Influenza-Like Illness (ILI), COVID-19, Estados de Saúde e de Doença, Primary care, Europe, Vigilância Epidemiológica, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Influenza Vaccines, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Sentinel Surveillance
Abstract: I-MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O’Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela MC Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
Published: 2022

7. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Author: Kissling, Esther, Hooiveld, Mariëtte, Martínez-Baz, Iván, Mazagatos, Clara, William, Naoma, Vilcu, Ana-Maria, Kooijman, Marjolein N, Ilić, Maja, Domegan, Lisa, Machado, Ausenda, de Lusignan, Simon, Lazar, Mihaela, Meijer, Adam, Brytting, Mia, Casado, Itziar, Larrauri, Amparo, Murray, Josephine-L K, Behillil, Sylvie, de Gier, Brechje, Mlinarić, Ivan, O'Donnell, Joan, Rodrigues, Ana Paula, Tsang, Ruby, Timnea, Olivia, de Lange, Marit, Riess, Maximilian, Castilla, Jesús, Pozo Sanchez, Francisco, Hamilton, Mark, Falchi, Alessandra, Knol, Mirjam J, Kurečić Filipović, Sanja, Dunford, Linda, Guiomar, Raquel, Cogdale, Jade, Cherciu, Carmen, Jansen, Tessa, Enkirch, Theresa, Basile, Luca, Connell, Jeff, Gomez, Verónica, Sandonis-Martin, Virginia, Bacci, Sabrina, Rose, Angela Mc, Pastore Celentano, Lucia, Valenciano, Marta, I-MOVE-COVID-19, ECDC primary care study teams, Conde-San Román, Patricia, Casas Flecha, Inmaculada, Oliva Dominguez, Jesus Angel, Delgado-Sanz, Concepcion, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Health Service Executive [Dublin] (HSE), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Oxford, Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Public Health Agency of Sweden, Instituto de Salud Carlos III [Madrid] (ISC), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des ARN et virus influenza - RNA Biology of Influenza Virus (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University College Dublin [Dublin] (UCD), UK Health Security Agency [London] (UKHSA), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), I-MOVE-COVID-19 and ECDC primary care study team Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O'Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo Fp Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairs, University of St Andrews. School of Medicine, Unión Europea. Comisión Europea. H2020, and European Centre for Disease Prevention and Control
Subjects: Test-negative design, RM, Delta variant, COVID-19 Vaccines, Epidemiology, [SDV]Life Sciences [q-bio], Multicentre study, Influenza, Human/prevention & control, MESH: Primary Health Care, Europe/epidemiology, MESH: Influenza Vaccines, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Influenza, Human, Humans, MESH: COVID-19, MESH: SARS-CoV-2, COVID-19/epidemiology, Vaccine effectiveness, QR355, MESH: Humans, Primary Health Care, vaccine effectiveness, SARS-CoV-2, MESH: Influenza, Human, Vaccination, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, MESH: Vaccination, NIS, multicentre study, RM Therapeutics. Pharmacology, Europe, Influenza Vaccines, MESH: COVID-19 Vaccines, SARS-COV-2, vaccine efffectiveness, MESH: Europe, QR355 Virology
Abstract: Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
Published: 2022

8. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study

Author: Kissling, Esther, Pozo, Francisco, Martínez‐Baz, Iván, Buda, Silke, Vilcu, Ana‐Maria, Domegan, Lisa, Mazagatos, Clara, Dijkstra, Frederika, Latorre‐Margalef, Neus, Kurečić Filipović, Sanja, Machado, Ausenda, Lazar, Mihaela, Casado, Itziar, Dürrwald, Ralf, van der Werf, Sylvie, O'Donnell, Joan, Linares Dopido, Juan Antonio, Meijer, Adam, Riess, Maximilian, Višekruna Vučina, Vesna, Rodrigues, Ana Paula, Mihai, Maria Elena, Castilla, Jesús, Goerlitz, Luise, Falchi, Alessandra, Connell, Jeff, Castrillejo, Daniel, Hooiveld, Mariette, Carnahan, Annasara, Ilić, Maja, Guiomar, Raquel, Ivanciuc, Alina, Maurel, Marine, Omokanye, Ajibola, Valenciano, Marta, I‐MOVE study team, European Centre for Disease Prevention and Control, EpiConcept [Paris], Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of Kalmar, Croatian Institute of Public Health [Zagreb] (CIPH), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Dirección General de Salud Pública, Public Health Agency of Sweden, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino National Medico-Military Institute for Research Development [Bucharest], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, University College Dublin [Dublin] (UCD), School of Social Sciences. Campus de Melilla. Univeristy of Granada, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), and tudy teams are very grateful to all patients, general practitioners, paediatricians, laboratory teams, and regional epidemiologists who have contributed to the studies. Participating laboratories submitted their sequences to GISAID (www.gisaid.org) for easy sharing with the central laboratory in Madrid. We would like to acknowledge Mia Brytting, who sadly passed away before publication. She is deeply missed.
Subjects: Pulmonary and Respiratory Medicine, Male, Adult, Adolescent, Epidemiology, [SDV]Life Sciences [q-bio], Vaccine Efficacy, Multicentre study, Young Adult, Influenza A Virus, H1N1 Subtype, Influenza, Human, Humans, Europe, influenza, influenza vaccine, multicentre study, vaccine effectiveness, Child, Aged, Vaccine effectiveness, Primary Health Care, Influenza vaccine, Influenza A Virus, H3N2 Subtype, Vaccination, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Middle Aged, vaccine effectiveness, multicentre study, Influenza, Europe, Infectious Diseases, Influenza Vaccines, Case-Control Studies, Child, Preschool, Female, influenza vaccine, influenza
Abstract: Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza. This project has received funding from the European Centre for Disease Prevention and Control with in the framework contract ECDC/2018/029. Sí
Published: 2022

9. Psychosocial care responses to terrorist attacks: a country case study of Norway, France and Belgium

Author: Lise Eilin Stene, Cécile Vuillermoz, Roel Van Overmeire, Johan Bilsen, Michel Dückers, Lisa Govasli Nilsen, Stéphanie Vandentorren, Norwegian Centre for Violence and Traumatic Stress Studies [Oslo, Norway] (NKVTS), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Vrije Universiteit Brussel (VUB), ARQ National Psychotrauma Centre [Diemen, the Netherlands], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), University of Groningen [Groningen], Norwegian University of Science and Technology (NTNU), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Malbec, Odile, Mental Health and Wellbeing research group, Public Health Sciences, and Social Psychology
Subjects: Mass casualty incidents, Norway, Health Policy, [SDV]Life Sciences [q-bio], Crisis intervention, Public Health, Environmental and Occupational Health, Psychiatric Rehabilitation, Program evaluation, Europe, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Mental health services, Belgium, Psychological trauma, Health services research, Humans, Terrorism, France, Emergencies, Psychosocial interventions
Abstract: Background The international terrorism threat urges societies to invest in the planning and organization of psychosocial care. With the aim to contribute to cross-national learning, this study describes the content, target populations and providers of psychosocial care to civilians after terrorist attacks in Norway, France and Belgium. Methods We identified and reviewed pre- and post-attack policy documents, guidelines, reports and other relevant grey literature addressing the psychosocial care response to terrorist attacks in Oslo/Utøya, Norway on 22 July 2011; in Paris, France on 13 November 2015; and in Brussels, Belgium on 22 March 2016. Results In Norway, there was a primary care based approach with multidisciplinary crisis teams in the local municipalities. In response to the terrorist attacks, there were proactive follow-up programs within primary care and occupational health services with screenings of target groups throughout a year. In France, there was a national network of specialized emergency psychosocial units primarily consisting of psychiatrists, psychologists and psychiatric nurses organized by the regional health agencies. They provided psychological support the first month including guidance for long-term healthcare, but there were no systematic screening programs after the acute phase. In Belgium, there were psychosocial intervention networks in the local municipalities, yet the acute psychosocial care was coordinated at a federal level. A reception centre was organized to provide acute psychosocial care, but there were no reported public long-term psychosocial care initiatives in response to the attacks. Conclusions Psychosocial care responses, especially long-term follow-up activities, differed substantially between countries. Models for registration of affected individuals, monitoring of their health and continuous evaluation of countries’ psychosocial care provision incorporated in international guidelines may strengthen public health responses to mass-casualty incidents.
Published: 2022

10. Letter to the editor: Increase of influenza vaccination coverage rates during the COVID-19 pandemic and implications for the upcoming influenza season in northern hemisphere countries and Australia

Author: Marco Del Riccio, Bruno Lina, Saverio Caini, Lisa Staadegaard, Sytske Wiegersma, Jan Kynčl, Béhazine Combadière, Chandini Raina MacIntyre, John Paget, Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Virology and human respiratory Pathologies - Virology and human respiratory Pathologies (VirPath), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), National Institute of Public Health [Prague], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University of New South Wales [Sydney] (UNSW), Università degli Studi di Firenze = University of Florence (UniFI), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie et des Maladies Infectieuses (CIMI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Gestionnaire, Hal Sorbonne Université
Subjects: Letter, Vaccination Coverage, Epidemiology, coverage rates, 03 medical and health sciences, 0302 clinical medicine, Virology, Influenza, Human, Humans, Pandemics, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, SARS-CoV-2, Vaccination, Public Health, Environmental and Occupational Health, Australia, COVID-19, 3. Good health, Influenza vaccination, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Influenza Vaccines, 030220 oncology & carcinogenesis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Seasons, influenza
Abstract: International audience
Published: 2021

11. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author: Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020
Subjects: Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract: I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
Published: 2021

12. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter?

Author: van Summeren, Jojanneke, Meijer, Adam, Aspelund, Guðrún, Casalegno, Jean Sebastien, Erna, Guðrún, Hoang, Uy, Lina, Bruno, de Lusignan, Simon, Teirlinck, Anne C., Thors, Valtýr, Paget, John, Ouziel, Antoine, Tardy, Jean-claude, Gaucherand, Pascal, Massardier, Jerome, Polazzi, Stephanie, Duclos, Antoine, Benchaib, Mehdi, Cartier, Regine, Jourdain, Marine, Ottmann, Michelle, Kramer, Rolf, Fiorini, Sylvie, Rivat, Nathalie, Mekki, Yahia, Fort-Jacquier, Julie, Barral, Maud-Catherine, Noelie, Vey, Haesebaert, Julie, Horvat, Come, Vidoni, Leo, Reynes, Jean-Marc, Eleouet, Jean-Francois, Josset, Laurence, Receveur, Matthieu, Javouhey, Etienne, Ploin, Dominique, Valette, Martine, Fanget, Remi, Targe, Sandrine Couray, Myar-Dury, Anne-Florence, Doret-Dion, Muriel, Massoud, Mona, Masson, Elsa, Bard, Emilie, Queromes, Gregory, Vanhems, Phillipe, Claris, Olivier, Butin, Marine, Ader, Florence, Bin, Sylvie, Gaymard, Alexandre, Morfin, Florence, Gillet, Yves, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Directorate of Health [Reykjavík], Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL), Landspitali National University Hospital of Iceland, University of Oxford [Oxford], Children’s Hospital [Reykjavik, Iceland], University of Iceland [Reykjavik], This study is performed as a side project of the RSV ComNet study. The aim of the RSV ComNet project is to measure the disease burden of RSV in children aged ≤5 years in primary care, and is funded by Sanofi Pasteur and AstraZeneca., VRS study group in Lyon: Antoine Ouziel, Jean-claude Tardy, Pascal Gaucherand, Jerome Massardier, Stephanie Polazzi, Antoine Duclos, Mehdi Benchaib, Regine Cartier, Marine Jourdain, Michelle Ottmann, Rolf Kramer, Sylvie Fiorini, Nathalie Rivat, Yahia Mekki, Julie Fort-Jacquier, Maud-Catherine Barral, Vey Noelie, Julie Haesebaert, Come Horvat, Leo Vidoni, Jean-Marc Reynes, Jean-Francois Eleouet, Laurence Josset, Matthieu Receveur, Etienne Javouhey, Dominique Ploin, Martine Valette, Remi Fanget, Sandrine Couray Targe, Anne-Florence Myar-Dury, Muriel Doret-Dion, Mona Massoud, Elsa Masson, Emilie Bard, Gregory Queromes, Phillipe Vanhems, Olivier Claris, Marine Butin, Florence Ader, Sylvie Bin, Alexandre Gaymard, Florence Morfin, Yves Gillet, and Lyon, VRS study group in
Subjects: Author's Correction, 0301 basic medicine, Veterinary medicine, viruses, Iceland, surveillance data, MESH: Respiratory Syncytial Virus, Human, Respiratory syncytial virus, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, Epidemiology, MESH: COVID-19, 030212 general & internal medicine, Respiratory system, Child, virus diseases, RSV, respiratory system, MESH: Iceland, MESH: Infant, Europe, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, epidemiology, France, Seasons, Winter season, Rapid Communication, medicine.medical_specialty, 2019-20 coronavirus outbreak, Surveillance data, Coronavirus disease 2019 (COVID-19), COVID-19 pandemic, Respiratory Syncytial Virus Infections, Biology, Virus, 03 medical and health sciences, MESH: Respiratory Syncytial Virus Infections, Virology, medicine, Humans, MESH: SARS-CoV-2, MESH: Humans, SARS-CoV-2, Public Health, Environmental and Occupational Health, Small children, COVID-19, Infant, MESH: France, 030104 developmental biology, Respiratory Syncytial Virus, Human, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, MESH: Seasons
Abstract: International audience; Since the introduction of non-pharmacological interventions to control COVID-19, respiratory syncytial virus (RSV) activity in Europe has been limited. Surveillance data for 17 countries showed delayed RSV epidemics in France (≥ 12 w) and Iceland (≥ 4 w) during the 2020/21 season. RSV cases (predominantly small children) in France and Iceland were older compared with previous seasons. We hypothesise that future RSV epidemic(s) could start outside the usual autumn/winter season and be larger than expected. Year-round surveillance of RSV is of critical importance.
Published: 2021

13. Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020

Author: Alessandra Falchi, Itziar Casado Buesa, Theresa Enkirch, Ana-Maria Vilcu, Mia Brytting, Adam Meijer, Janneke Hendriksen, Josie Murray, Jesús Castilla, Debbie Sigerson, Diogo F P Marques, Vincent Enouf, Sylvie Behillil, Mariëtte Hooiveld, AnnaSara Carnahan, Iván Martínez-Baz, Marta Valenciano, Esther Kissling, Frederika Dijkstra, Naoma William, Marit M A de Lange, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Public Health Agency of Sweden, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de Virologie [UNIV Corse-Inserm] (EA7310), Université Pascal Paoli (UPP)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Union. Grant Number: 101003673, European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pascal Paoli (UPP), and University of St Andrews. School of Medicine
Subjects: Male, Epidemiology, [SDV]Life Sciences [q-bio], Target groups, E-DAS, Logistic regression, SARS‐CoV‐2, 0302 clinical medicine, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Odds Ratio, 030212 general & internal medicine, Respiratory Tract Infections, 0303 health sciences, Vaccination, Respiratory infection, Case-control study, Orthomyxoviridae, influenza vaccination, multicentre study, 3. Good health, Europe, Infectious Diseases, Influenza Vaccines, Original Article, Female, Test-negative design, Pulmonary and Respiratory Medicine, RM, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Influenza vaccination status, case-control study, Primary care, Multicentre study, 03 medical and health sciences, SDG 3 - Good Health and Well-being, COVID‐19, Internal medicine, Influenza, Human, medicine, Humans, 030304 developmental biology, Primary Health Care, case‐control study, business.industry, SARS-CoV-2, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, Original Articles, Odds ratio, NIS, Influenza vaccination, RM Therapeutics. Pharmacology, Logistic Models, test‐negative design, Case-Control Studies, business
Abstract: The I‐MOVE‐COVID‐19 network has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no 101003673. Background : Claims of influenza vaccination increasing COVID-19 risk are circulating. Within the I-MOVE-COVID-19 primary care multicentre study, we measured the association between 2019-20 influenza vaccination and COVID-19. Methods : We conducted a multicentre test-negative case-control study at primary care level, in study sites in five European countries, from March to August 2020. Patients presenting with acute respiratory infection were swabbed, with demographic, 2019-20 influenza vaccination and clinical information documented. Using logistic regression, we measured the adjusted odds ratio (aOR), adjusting for study site and age, sex, calendar time, presence of chronic conditions. The main analysis included patients swabbed ≤7 days after onset from the three countries with
Published: 2021

14. Addressing vulnerabilities in communities facing infectious disease threats

Author: Ruth Kutalek, David Napier, Roman Rodyna, John Paget, Jacob Osborne, Syed Masud Ahmed, Tamara Giles-Vernick, Michel L. A. Dückers, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), University College of London [London] (UCL), Anthropologie et écologie de l’émergence des maladies - Anthropology and Ecology of Disease Emergence, Institut Pasteur [Paris], Medizinische Universität Wien = Medical University of Vienna, Public Health Center [Kyiv, Ukraine], Ministry of Health of Ukraine, BRAC University [Dhaka, Bangladesh], ARQ National Psychotrauma Centre [Diemen, the Netherlands], This project has received funding from the EU Horizon 2020 Research and Innovation Programme under Grant Agreement No. 825671., European Project: 825671,H2020-SC1-2018-Single-Stage-RTD ,SoNAR-Global(2019), Social Psychology, and Institut Pasteur [Paris] (IP)
Subjects: 2019-20 coronavirus outbreak, 030505 public health, Community engagement, Coronavirus disease 2019 (COVID-19), Health Policy, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public Health, Environmental and Occupational Health, Social Sciences, Communicable Diseases, 3. Good health, [SHS]Humanities and Social Sciences, Viewpoints, 03 medical and health sciences, 0302 clinical medicine, Infectious disease (medical specialty), Political science, Pandemic, Humans, 030212 general & internal medicine, Social science, 0305 other medical science, ComputingMilieux_MISCELLANEOUS
Abstract: Key points - Infectious threats, including pandemics, require a careful understanding of local contexts and global processes. Here, the social sciences can offer important contributions. - Responses to infectious diseases should use community engagement that addresses wide-ranging vulnerabilities, using concepts and methods from both social science and traditional infectious disease science.
Published: 2021

15. What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia?

Author: Louisa Flander, Evelien Dekker, Berit Andersen, Mette Bach Larsen, Robert J Steele, Nea Malila, Tytti Sarkeala, Manon van der Vlugt, Clasine de Klerk, Bart Knottnerus, Lucinda Bertels, Anke Woudstra, Manon C.W. Spaander, Mirjam Fransen, Sirpa Heinavaara, Mary Dillon, Driss Ait Ouakrim, Mark Jenkins, University of Melbourne, Amsterdam UMC, Aarhus University, University of Dundee, Finnish Cancer Registry, Netherlands Institute for Health Services Research, Erasmus University Rotterdam, Vrije Universiteit Amsterdam, University of Amsterdam, Department of Information and Service Management, Aalto-yliopisto, Aalto University, Gastroenterology and hepatology, Public and occupational health, Gastroenterology and Hepatology, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, Amsterdam Gastroenterology Endocrinology Metabolism, General practice, ACS - Heart failure & arrhythmias, APH - Personalized Medicine, APH - Health Behaviors & Chronic Diseases, APH - Quality of Care, APH - Global Health, Socio-Medical Sciences (SMS), and Gastroenterology & Hepatology
Subjects: Male, screening, Australia, population, colorectal cancer, Hematology, General Medicine, SDG 3 - Good Health and Well-being, Oncology, Occult Blood, Humans, Mass Screening, Female, epidemiology, helth care, Colorectal Neoplasms, Early Detection of Cancer
Abstract: Funding Information: This work was supported by the University of Melbourne, Melbourne School of Population and Global Health, Human Ethics Advisory Group. Project title: “Consultation to understand international differences in bowel cancer screening participation,” ID 2057312.1 Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Engagement Research Funding from the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia. Publisher Copyright: © The Author(s) 2022. Background: Colorectal cancer (CRC) is the second most diagnosed cancer in men and women and second most common cause of cancer death in Australia; Australia’s CRC incidence and mortality are among the world’s highest. The Australian National Bowel Cancer Screening Program began in 2006; however, only 33% of those approached for the first time by the Program between 2018 and 2019 returned the kit. Of the 5.7 million kits sent during this period, only 44% were returned. Our aim was to identify practices and features of national bowel cancer screening programs in countries with similar programs but higher screening participation, to identify potential interventions for optimising Australian CRC screening participation. Methods: We searched published and grey literature for CRC screening programs reporting at least 50% screening participation using postal invitation and free return of iFOBT home kits. Interviews were conducted with cancer registry staff and academic researchers, focused on participant and practitioner engagement in screening. Results: National programs in Netherlands, Scotland, Denmark, and Finland reported over 50% screening participation rates for all invitation rounds. Shared characteristics include small populations within small geographic areas relative to Australia; relatively high literacy; a one-sample iFOBT kit; national registration systems for population cancer screening research; and screening program research including randomised trials of program features. Conclusions: Apart from the one-sample kit, we identified no single solution to persistent Australian low uptake of screening. Research including randomised trials within the program promises to increase participation. Impact: This screening program comparison suggests that within-program intervention trials will lead to increased Australian screening participation.
Published: 2022

16. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort

Author: Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Gherasim, Alin, Brytting, Mia, Domegan, Lisa, Gomez, Veronica, Meijer, Adam, Lazar, Mihaela, Vucina, Vesna Visekruna, Duerrwald, Ralf, van der Werf, Sylvie, Larrauri, Amparo, Enkirch, Theresa, O'Donnell, Joan, Guiomar, Raquel, Hooiveld, Mariette, Petrovic, Goranka, Stoian, Elena, Penttinen, Pasi, Valenciano, Marta, Preuss, Ute, Tolksdorf, Kristin, Biere, Barbara, Smallfield, Maria, Wedde, Marianne, Falchi, Alessandra, Masse, Shirley, Villechenaud, Natacha, Souty, Cecile, Blanchon, Thierry, Launay, Titouan, Enouf, Vincent, Behillil, Sylvie, Lina, Bruno, Valette, Martine, Mazagatos, Clara, Casas, Inmaculada, Garcia Comas, Luis, Insua Marisquerena, Maria Esther, Carlos Galan, Juan, Castilla, Jesus, Garcia Cenoz, Manuel, Navascues, Ana, Quinones Rubio, Carmen, Ibanez Perez, Ana Carmen, Martinez Ochoa, Eva, Blasco, Miriam, Gimenez Duran, Jaume, Maria Vanrell, Juana, Reina, Jordi, Castrillejo, Daniel, Wiman, Asa, Hunt, Meadhbh, Joyce, Michael, Levis, Olga, Collins, Claire, Dunford, Linda, Bennett, Charlene, Moran, Joanne, Tuite, Grainne, Connell, Jeff, de Gascun, Cillian, Rodrigues, Ana Paula, Machado, Ausenda, Nunes, Baltazar, Kislaya, Irina, Costa, Ines, Conde, Patricia, Cristovao, Paula, Pechirra, Pedro, Borges, Vitor, Bagheri, Mariam, van den Brink, Sharon, Dijkstra, Frederika, Goderski, Gabriel, van der Hoek, Wim, de Lange, Marit, Marzec, Ton, Overduin, Pieter, Reukers, Daphne, Teirlinck, Anne, Wijsman, Lisa, Donker, Ge, Mihai, Maria Elena, Cherciu, Carmen Maria, Alexandrescu, Viorel, Kaic, Bernard, Filipovic, Sanja Kurecic, Novosel, Iva Pem, Makaric, Zvjezdana Lovric, Zajec, Martina, Drazenovic, Vladimir, Moren, Alain, I-MOVE Primary Care Study Team, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)
Subjects: vacunas de la gripe, Male, 0301 basic medicine, potencia vacunal, Epidemiology, [SDV]Life Sciences [q-bio], humanos, Gripe, adolescente, Hemagglutinin Glycoproteins, Influenza Virus, virus de la influenza A, 0302 clinical medicine, infecciones del tracto respiratorio, memoria inmunológica, vigilancia centinela, Determinantes de Saúde e Doença, Medicine, 030212 general & internal medicine, Respiratory Tract Infections, mediana edad, Vaccine effectiveness, anciano, birth cohorts, Birth cohorts, Estado de Saúde e Doença, resultado del tratamiento, Vaccination, Age Factors, Imprinting, adulto, Middle Aged, multicentre study, Europe, Treatment Outcome, Influenza A virus, Época 2018-2019, Influenza Vaccines, Population Surveillance, Female, Seasons, imprinting, influenza, Birth cohort, A(H3N2), Adult, Adolescent, Primary care, Multicentre study, vacunación, 03 medical and health sciences, vigilancia de la población, Virology, Influenza, Human, Humans, ddc:610, Vacina Antigripal, EuroEVA, Vaccine Potency, Aged, vaccine effectiveness, business.industry, Influenza A Virus, H3N2 Subtype, Research, Efetividade, Public Health, Environmental and Occupational Health, Influenza a, Influenza, estaciones (meteorología), 030104 developmental biology, influenza vaccination, test negative case control, vaccine effectiveness, 610 Medizin und Gesundheit, business, Immunologic Memory, Sentinel Surveillance, Demography
Abstract: Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-year-olds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.
Published: 2019

17. Vulnerability assessment tools for infectious threats and antimicrobial resistance: a scoping review protocol

Author: A. David Napier, Maren Jeleff, Ruth Kutalek, Lisa Lehner, Tamara Giles-Vernick, Michel L. A. Dückers, Elena Jirovsky, Medizinische Universität Wien = Medical University of Vienna, Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM), Netherlands Institute for Health Services Research [Utrecht] (NIVEL), University College of London [London] (UCL), The scoping review is part of the SoNAR-Global project which has received funding from the European Union’s Horizon 2020 research and innovation program (Grant Agreement Number: 825671). The funders did not play a role in decision to publish or developing the protocol., European Project: 825671,H2020-SC1-2018-Single-Stage-RTD ,SoNAR-Global(2019), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), and HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)
Subjects: vulnerability assessment, Knowledge management, MESH: Drug Resistance, Microbial, Vulnerability, MEDLINE, Global Health, MESH: Risk Assessment, Communicable Diseases, Risk Assessment, [SHS]Humanities and Social Sciences, 03 medical and health sciences, one health, 0302 clinical medicine, Vulnerability assessment, infectious disease outbreaks, Global health, Protocol, Medicine, Humans, medical anthropology, 030212 general & internal medicine, MESH: Humans, business.industry, MESH: Research Design, Drug Resistance, Microbial, General Medicine, Grey literature, Checklist, 3. Good health, One Health, Data extraction, 13. Climate action, Research Design, Vulnerable groups, MESH: Communicable Diseases, business, MESH: Systematic Reviews as Topic, 030217 neurology & neurosurgery, Systematic Reviews as Topic
Abstract: IntroductionThis protocol will guide and explain the working process of a systematic scoping review on vulnerability assessment tools in the field of infectious disease outbreaks and antimicrobial resistance (AMR) crises. The scoping review will appraise existing tools or methodologies to identify local level vulnerabilities in the context of infectious disease outbreaks and AMR. Due to this focus on infectious threats and AMR, the review also considers articles using a ‘One Health’ approach to assess the vulnerability of individuals, groups and practices in human–animal–environment interactions. Given the broad nature of vulnerability, we aim to allocate studies discerning the process of identifying vulnerable or at-risk groups during a crisis, instead of studies taking vulnerability only as a starting point. Because considerable research has been conducted on vulnerability, disasters and climate change, we will also assemble tools developed from these fields. To our knowledge, this is the first planned systematic scoping review of vulnerability assessment tools for disease outbreaks and AMR, taking into account practices at the human–animal–environment interface that can lead to increased risk of exposure of individuals to infections, pathogen spillovers or epidemics.Methods and analysisTo develop the protocol, we used the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols checklist (PRISMA-P 2015) in compliance with the PRISMA Extension for Scoping Reviews Explanation and Elaboration. With the assistance of an experienced research librarian, we developed the search strategy, which targeted the following databases: Medline, Global Health database, Web of Science and Embase. A second strategy was developed for Epistemonikos, African Journals Online and Global Index Medicus because these databases do not provide the infrastructure for an advanced search. We consider studies published between 1978 and 2019 and include articles, book chapters, websites and grey literature from selected non-governmental organisations and non-profit organisations working in the health field. We contact them directly regarding whether they are working with or have developed a vulnerability assessment tool. To address the dynamic nature of our investigation, we develop a flow diagram which we continually update to reflect the selection process. Two reviewers (MJ and LL) independently screen the literature and resolve conflicts through discussion rounds. Data extraction will be conducted by four researchers (MJ, LL, EJ and RK) through inductive and deductive coding. Extracted data will be systematically compared and divergences highlighted.Ethics and disseminationEthical approval is not required because this study does not involve collection of primary data. The purpose of this review is to disseminate a catalogue of vulnerability assessment tools and a brief summary of key results and recommendations for SoNAR-Global partners in Bangladesh, Ukraine and Uganda. The catalogue will be made publicly available. On the basis of our results, SoNAR-Global partners will pilot one of these tools.
Published: 2019

18. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014

Author: François G. Schellevis, Raquel Guiomar, Zhibin Peng, Phuong Vu Mai Hoang, Brechla Moreno, Juan Yang, Cheryl Cohen, Lynnette Brammer, Jenny Lara, Hongjie Yu, Mai thi Quynh Le, Joshua A. Mott, Rodrigo Fasce, Gabriela Kusznierz, Simona Puzelli, Doménica de Mora, Leticia Castillo, Selim Badur, Akerke Ospanova, Vernon J. Lee, Liza Lopez, Richard Njouom, Douglas M. Fleming, Coulibaly Daouda, Nurhayati, Juan Manuel Rudi, Clotilde El-Guerche Séblain, Li Wei Ang, Joseph S. Bresee, Celina de Lozano, Sonam Gyeltshen, Maria Zambon, Maria Luisa Matute, Norosoa Harline Razanajatovo, Saverio Caini, Amal Barakat, Marie-Astrid Vernet, Alla Mironenko, Angel Balmaseda, Alexey Clara, Walquiria Aparecida Ferreira de Almeida, Richard Pebody, Herman Kosasih, Cláudio Maierovitch Pessanha Henriques, Marietjie Venter, Caterina Rizzo, Meral Akcay Ciblak, Olha Holubka, Gideon O. Emukule, Fatima el Falaki, Winston Andrade, Herve A. Kadjo, Alfredo Bruno, Kate Pennington, Lyazzat Kiyanbekova, Ana Paula Rodrigues, Rhonda Owen, John Paget, Peter Spreeuwenberg, Sue Q. Huang, Jean-Michel Heraud, Sonam Wangchuk, Luzhao Feng, Netherlands Institute for Health Services Research, Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni', Department of Health and Ageing, Influenza Surveillance Section, Surveillance Branch, Office of Health Protection (DHAISS), Department of Health and Ageing, Influenza Surveillance Section, Surveillance Branch, Office of Health Protection, Woden, ACT, Australia, Office of Health Protection, Woden, ACT, Australia (DHAISS), Ministry of Health [Bhoutan], Ministry of Health [Brasília, Brazil], Centre Pasteur du Cameroun, Réseau International des Instituts Pasteur (RIIP), Instituto de Salud Pública de Chile (ISP), Chinese Centre for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Ministry of Health [Costa Rica], Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud de El Salvador (MINSAL), Public Health England [London], Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), US Centers for Disease Control, Ministry of Health [Honduras] (SESAL), US Naval Medical Research Unit n°2, Istituto Superiore di Sanita [Rome], Institut Pasteur de Côte d'Ivoire, Institut National d'Hygiène Publique [Côte d'Ivoire] (INHP), Astana Center of Sanitary Epidemiology Expertise, Centers for Disease Control and Prevention [Kenya], U.S. Public Health Service (USPHS), Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Ministry of Health [Morocco], Institute of Environmental Science and Research (ESR), Ministry of Health [Nicaragua] (MINSA), National Influenza Center, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Ministry of Health [Singapore], Centers for Disease Control and Prevention, University of Pretoria [South Africa], University of the Witwatersrand [Johannesburg] (WITS), National Institute for Communicable Diseases [Johannesburg] (NICD), Istanbul University, National Academy of Medical Sciences of Ukraine, Centers for Disease Control and Prevention [Atlanta] (CDC), National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Chercheur indépendant, Sanofi Pasteur [Lyon, France], VU University Medical Center [Amsterdam], The Global Influenza B Study is funded by an unrestricted research grant from Sanofi Pasteur., The Global Influenza B Study group also includes the following members: Binay Thapa 4, Sangay Zangmo 4, Guy Vernet 6, Patricia Bustos 7, Patricio Loyola 7, Joanna Ellis 12, Antonino Bella 19, Maria Rita Castrucci 18, Gulzhan Muratbayeva 45, Julia Guillebaud 26, Laurence Randrianasolo 46, Ausenda Machado 47, Pedro Pechirra 32, Jeffery Cutter 34, Raymond Tzer Pin Lin 34. 45 Centers for Disease Control and Prevention, Central Asia Regional Office, Almaty, Kazakhstan 46 Epidemiology Unit, Institut Pasteur of Madagascar, Antananarivo, Madagascar 47 National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal, APH - Quality of Care, APH - Aging & Later Life, and General practice
Subjects: 0301 basic medicine, Male, Databases, Factual, Distribution (economics), CHILDREN, Global Health, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, 1108 Medical Microbiology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Influenza A Virus, H3N2 subtype, 030212 general & internal medicine, Young adult, Child, POPULATION, education.field_of_study, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Age Factors, Middle Aged, 3. Good health, Global Influenza B Study group, Infectious Diseases, INFECTIONS, Influenza A virus, Child, Preschool, H3N2 Subtype, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, BURDEN, Life Sciences & Biomedicine, Age distribution, 0605 Microbiology, Adult, medicine.medical_specialty, Surveillance data, Adolescent, Population, UNITED-STATES, Microbiology, Virus, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Young Adult, Age Distribution, Influenza, Human, medicine, Humans, H1N1 Subtype, COHORT, lcsh:RC109-216, education, Disease burden, METAANALYSIS, Aged, Science & Technology, business.industry, Public health, Influenza A Virus, H3N2 Subtype, Infant, Newborn, Infant, 1103 Clinical Sciences, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Estados de Saúde e de Doença, Influenza B Virus, Influenza, Influenza B virus, Meta-analysis, 030104 developmental biology, H1N1 subtype, Virus type, RISK-FACTORS, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract: The database of the Global Influenza B Study was created by collecting surveillance datasets from each of the participating countries. These national datasets are owned by the participating countries, and thus cannot be shared publicly. Researchers interested in obtaining the country-specific datasets may contact the individuals listed below for further details regarding data access.Argentina (Santa Fe Province): Gabriela Kusznierz (labconi@yahoo.com.ar)Australia: Kate Pennington (kate.pennington@health.gov.au)Bhutan: Sonam Wangchuk (swangchuk@health.gov.bt)Brazil: Cláudio Maierovitch Pessanha Henriques (claudio.henriques@saude.gov.br)Cameroon: Guy Vernet (vernet@pasteur-yaounde.org)Chile: Rodrigo Fasce (rfasce@ispch.cl)China: Feng Luzhao (fenglz@chinacdc.cn)Costa Rica: Alexey W. Clara (wclara@cdc.gov)Ecuador: Alfredo Bruno (alfredobruno@yahoo.es)El Salvador: Alexey W. Clara (wclara@cdc.gov)England: Maria Zambon (maria.zambon@phe.gov.uk)Guatemala: Alexey W. Clara (wclara@cdc.gov)Honduras: Alexey W. Clara (wclara@cdc.gov)Indonesia: Herman Kosasih (hermaninarespond@gmail.com)Italy: Caterina Rizzo (caterina.rizzo@iss.it)Ivory Coast: Herve A. Kadjo (hervekadjo@pasteur.ci)Kazakhstan: Gulzhan Muratbayeva (hnv2@cdc.gov)Kenya: Joshua Mott (zud9@cdc.gov)Madagascar: Jean-Michel Heraud (jmheraud@pasteur.mg)Morocco: Amal Barakat (amal.barakat@yahoo.fr)New Zealand: Sue Huang (sue.huang@esr.cri.nz)Nicaragua: Alexey W. Clara (wclara@cdc.gov)Panama: Alexey W. Clara (wclara@cdc.gov)Portugal: Ana Paula Rodrigues (ana.rodrigues@insa.min-saude.pt)Singapore: Vernon Lee (vernonljm@hotmail.com)South Africa: Cheryl Cohen (cherylc@nicd.ac.za)Turkey: Meral Akcay Ciblak (ciblakm@yahoo.com)Ukraine: Alla Mironenko (miralla@ukr.net)Viet Nam: Le Thi Quinh Mai (lom9@hotmail.com); International audience; BACKGROUND:Influenza disease burden varies by age and this has important public health implications. We compared the proportional distribution of different influenza virus types within age strata using surveillance data from twenty-nine countries during 1999-2014 (N=358,796 influenza cases).METHODS:For each virus, we calculated a Relative Illness Ratio (defined as the ratio of the percentage of cases in an age group to the percentage of the country population in the same age group) for young children (0-4 years), older children (5-17 years), young adults (18-39 years), older adults (40-64 years), and the elderly (65+ years). We used random-effects meta-analysis models to obtain summary relative illness ratios (sRIRs), and conducted meta-regression and sub-group analyses to explore causes of between-estimates heterogeneity.RESULTS:The influenza virus with highest sRIR was A(H1N1) for young children, B for older children, A(H1N1)pdm2009 for adults, and (A(H3N2) for the elderly. As expected, considering the diverse nature of the national surveillance datasets included in our analysis, between-estimates heterogeneity was high (I2>90%) for most sRIRs. The variations of countries' geographic, demographic and economic characteristics and the proportion of outpatients among reported influenza cases explained only part of the heterogeneity, suggesting that multiple factors were at play.CONCLUSIONS:These results highlight the importance of presenting burden of disease estimates by age group and virus (sub)type.
Published: 2018

19. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016

Author: SONIA PEREZ CASTRO, Amparo Larrauri, Catherine Moore, Sylvie Van der WERF, Nuria Torner, Pedro Pechirra, FALCHI Alessandra, Bruno Lina, Lisa Domegan, Cathriona Kearns, Thea Kølsen Fischer, Maria Concepcion Delgado Sanz, Francisco Pozo, Simon De Lusignan, Lidia Brydak, Santiago Melón García, Ramona Trebbien, Inmaculada Casas, Richard Pebody, Silvia Jiménez-Jorge, European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), University of Turku, Turku University Hospital (TYKS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Specific country acknowledgements Denmark: For Denmark the test results for respiratory syncytial virus in the season 2015/16 were obtained from the Danish Microbiology Database (MiBa, http://miba.ssi.dk), which contains all electronic reports from departments of clinical microbiology in Denmark since 2010, and we acknowledge the collaboration with the MiBa Board of Representatives. France: For primary care, sentinel networks: all GPs, paediatricians and their patients for providing the samples tested. For the hospital laboratory network, RENAL: Ile de France, - Ambroise Pare, Avicenne, Bichat, Bicêtre, Henri Mondor, Versailles, Necker, Paul Brousse, Pitie Salpetrière, Robert Debré, Saint-Louis, Cochin, Trousseau-Saint Antoine-Tenon, Pontoise, Poissy and Foch. Other regions: Strasbourg, Dijon, Reims, Nancy, Besançon, Lille, Amiens, Caen, Brest, Rennes, Orléans, Tours, Rouen, Angers, Nantes, Aix-en-Provence, Annecy, Bordeaux, Chambéry, Clermont-Ferrand, Grenoble, Limoges, Lyon, Marseille, Montpellier, Nice, Poitiers, Saint-Etienne and Toulouse. Hôpitaux Militaires: HIA Begin – Dr A. MERENS, HIA Legouest – Dr Y. ROBERT, HIA Clermont Tonnerre – Dr P. LE GUEN, Hôpitaux Militaires: Bordeaux – Lyon - Marseille – Toulon. Ireland: We would like to acknowledge the Irish sentinel GP network, hospital clinicians and clinical microbiologists for taking and providing specimens to the National Virus Reference Laboratory (NVRL) for RSV testing. Latvia: Laboratory specialists A.Aniščenko, T. Kolupajeva, for performing virological analyses. The Netherlands: GPs and their patients for taking and providing specimens, clinical microbiologists from diagnostic laboratories for providing weekly diagnostics virological reports, technicians in the laboratories for performing virological analyses. Poland: All members of NIC in Poland working in years 2010-2016, Voivodship Sanitary Epidemiological Stations in Poland. Portugal: We acknowledge the Colleagues from the National Institute of Health Dr Ricardo Jorge, I.P. that contributed to the supported of the National Influenza Surveillance Program. We acknowledge to the Portuguese GP Sentinel Network, to physicians from Emergency and Obstetric Units Network, to physicians of the EuroEva project and to the Portuguese Laboratory Network for Influenza Diagnosis. Spain: We would like to acknowledge all the professionals participating in the Spanish Influenza Surveillance System. Sweden: Contributing laboratories and paediatric clinics., We express our gratitude to the European Surveillance System data management team, especially Marius Valentin Valcu, Adrian Prodan and Cátia Cunha. We thank Silviu Lucian Ionescu for calculation of barycentres. We thank Cornelia Adlhoch for supporting the data collection for RSV within TESSy. We are grateful to Tommi Kärki for the support with preparation of Figure 2. We would also like to thank Julien Beauté, Phillip Zucs and Mike Catchpole for their valuable comments. We acknowledge all the members of the European Influenza Surveillance Network for their tireless work for influenza surveillance in European Union/European Economic Area countries and for testing for RSV and including the RSV detections in the weekly reporting., European Influenza Surveillance Network members from the contributing countries Denmark: Ramona Trebbien, Hanne-Dorthe Emborg, Tyra Grove Krause and Thea K Fischer (Statens Serum Institut, Copenhagen). Estonia: Natalja Kuznetsova, Liidia Dotsenko (Estonian Health Board, Laboratory of Communicable Diseases, Tallinn) and Olga Sadikova (Estonian Health Board, Department of CD surveillance and control, Influenza Centre, Tallinn). France: Sylvie Behillil (Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, CNR des Virus Influenzae, Institut Pasteur, Paris), Thierry Blanchon (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), F75012 Paris, France), Lisandru Capai (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), F75012 Paris, France), F75012, Paris, EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte), Jean-Marie Cohen (Open Rome (Organize and Promote Epidemiological Network), Paris, France, Réseau des GROG, Paris), Vincent Enouf (Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, CNR des Virus Influenzae, Institut Pasteur, Paris), Alessandra Falchi (EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte), Caroline Guerrisi (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), F75012 Paris, France), Bruno Lina (Laboratoire de Virologie, CNR des virus influenza, Institut des Agents Infectieux, Groupement Hospitalier Nord des HCL, Lyon, Laboratoire Virpath, CIRI Inserm U1111, CNRS 5308, ENS, UCBL, Faculté de Médecine LYON Est, Université de Lyon, Lyon), Thomas Hanslik (AP-HP, Hôpital Ambroise Paré, Service de Médecine interne, F-92100 Boulogne Billancourt, France), Shirley Masse (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), F75012 Paris, France, EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte), Anne Mosnier (Open Rome (Organize and Promote Epidemiological Network), Paris, France, Réseau des GROG, Paris), Clément Turbelin (Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP), F75012 Paris, France), Martine Valette (Laboratoire de Virologie, CNR des virus influenza, Institut des Agents Infectieux, Groupement Hospitalier Nord des HCL, Lyon, Laboratoire Virpath, CIRI Inserm U1111, CNRS 5308, ENS, UCBL, Faculté de Médecine LYON Est, Université de Lyon, Lyon), Sylvie van der Werf (Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, CNR des Virus Influenzae, Institut Pasteur, Paris). Germany: Brunhilde Schweiger, Janine Reiche, Barbara Biere (National Influenza Centre, Robert Koch Institute, Berlin) and Silke Buda (Respiratory Infections Unit, Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin). Iceland: Gudrun Erna Baldvinsdottir (Department of Clinical Microbiology at Landspitali University Hospital, Reykjavik). Ireland: Lisa Domegan and Joan O Donnell (HSE-Health Protection Surveillance Centre, Dublin), Christina Byrne, Paul O’Reilly, Joanne Moran, Allison Waters and Cillian de Gascun (National Virus Reference Laboratory, University College Dublin, Dublin). Latvia: Natalija Zamjatina and Gatis Pakarna (Riga East University Hospital, Latvian Centre of Infectious Diseases, Riga) and Raina Nikiforova (Centre for Disease Prevention and Control, Riga). Malta: Jackie Maistre Melillo and Tanya Melillo (Infectious Disease Prevention and Control Unit, Msida). The Netherlands: Adam Meijer (Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven), Anne Teirlinck (Centre for Infectious Diseases, Epidemiology and Surveillance, RIVM) and Gé Donker (NIVEL, Netherlands Institute for Health Services Research, Utrecht). Poland: Lidia B. Brydak and Katarzyna Cieślak (National Influenza Centre, Department of Influenza Research, National Institute of Public Health - National Institute of Hygiene, Warsaw). Portugal: Raquel Guiomar, Paula Cristóvão and Pedro Pechirra (National Influenza Reference Laboratory, Infectious Diseases Department, National Institute of Health Dr Ricardo Jorge, I.P., Lisbon) and Ana Paula Rodrigues (Department of Epidemiology, National Institute of Health Dr Ricardo Jorge, I.P., Lisbon). Slovenia: Katarina Prosenc (National Laboratory for Health, Environment and Food, Slovenia) and Maja Socan (Public Health Institute, Slovenia). Spain: Amparo Larrauri, Concepcion Delgado-Sanz, Jesús Oliva, (National Centre of Epidemiology, CIBERESP, Instituto de Salud Carlos III, Madrid), Silvia Jiménez-Jorge (National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid), Francisco Pozo, Inmaculada Casas (National Centre of Microbiology, Instituto de Salud Carlos III, Madrid), Jose María Navarro (Hospital Virgen de las Nieves de Granada), Virtudes Gallardo (Consejería de Salud, Andalucía), Manuel Omeñaca (HU Miguel Servet), Elisa Marco (Dirección General de Salud Pública, Aragón), Santiago Melón (HU Central de Asturias), Ismael Huerta (Dirección General de Salud Pública, Asturias), Jordi Reina (Hospital Son Espases de Palma de Mallorca), Carmen Pérez González (Hospital Dr Negrín de Las Palmas de Gran Canarias), Lucas González (Dirección General de Salud Pública, Canarias), Microbiologists of the Hospital Network of Castilla La Mancha, Maria Victoria García Rivera (Servicio de Epidemiología, Consejería de Sanidad), Raúl Ortiz de Lejarazu (National Influenza Center, Hospital Clínico Universitario Valladolid), Tomás Vega (Observatorio de Salud Pública, Castilla y León), Mª Ángeles Marcos (Hospital Clínico de Barcelona), Nuria Torner (Agència de Salut Pública, CIBERESP, Cataluña), Sonia Perez Castro (CH Meixoeiro, Vigo), Juan Garcia Costa (CH Santa María Nai, Ourense), María Jesús Purriños (Dirección Xeral Saúde Pública, Galicia), Antonio Moreno Docón (Hospital Virgen de la Arrixaca), Miriam Fernández (Clínica Universitaria de Navarra), Carmen Ezpeleta (Complejo Hospitalario de Navarra), Jesús Castilla (Instituto de Salud Pública, CIBERESP, Navarra), Miriam Blasco (Hospital de La Rioja de Logroño), Carmen Quiñones (Dirección General de Salud Pública y Consumo, La Rioja), José López Barba (Hospital de INGESA), Ana Rivas (Consejería de Sanidad y Bienestar Social, Ceuta). Sweden: AnnaSara Carnahan, Sarah Axelsson, Hélène Englund, Marie Rapp and Mia Brytting (Public Health Agency of Sweden, Stockholm). United Kingdom: Richard Pebody (PHE, Colindale), Joanna Ellis (PHE, Colindale), and Maria Zambon (PHE, Colindale), Simon de Lusignan (Royal College of General Practitioners, London), Naomh Gallagher, Chris Nugent and Cathriona Kearns (Public Health Agency, Northern Ireland), Simon Cottrell and Catherine Moore (Public Health Wales, Cardiff), Jim McMenamin (HPS, Glasgow).
Subjects: 0301 basic medicine, Infecções Respiratórias, Male, Pediatrics, medicine.medical_specialty, Epidemiology, [SDV]Life Sciences [q-bio], respiratory syncytial virus, 030106 microbiology, Respiratory Syncytial Virus Infections, Surveillance and Outbreak Report, Virus, 03 medical and health sciences, 0302 clinical medicine, Virology, medicine, media_common.cataloged_instance, Humans, In patient, geographic spread, 030212 general & internal medicine, ddc:610, European union, Respiratory system, Epidemics, Respiratory Tract Infections, media_common, Retrospective Studies, Respiratory tract infections, Geography, seasonality, Public Health, Environmental and Occupational Health, Respiratory infection, RSV, Retrospective cohort study, Seasonality, medicine.disease, Europe, Population Surveillance, Respiratory Syncytial Virus, Human, Female, Seasons, 610 Medizin und Gesundheit, Sentinel Surveillance
Abstract: Respiratory syncytial virus (RSV) is considered the major pathogen causing severe lower respiratory tract infections among infants and young children [1]. RSV is the most common cause of hospitalisation for acute lower respiratory tract infection in children younger than 5 years and is estimated to cause between 66,000 and 199,000 deaths worldwide every year [2]. Its significance in causing substantial morbidity and hospitalisation in the first year of life has been affirmed in a recent study and a meta-analysis [3,4]. In England, average annual hospital admission rates are 35.1 per 1,000 children younger than 1 year and 5.31 per 1,000 children aged 1–4 years [5]. In addition to children, RSV causes a substantial disease burden in elderly people and patients with chronic obstructive pulmonary disease [6,7]. RSV causes seasonal epidemics worldwide [8], with one to two epidemics each year [9] following latitudinal gradients in timing, duration, seasonal amplitude and between-year variability [8,9]. In some studies, the seasonal periodicity has been connected to climatic factors [9-11], but a common factor that explains all observed periodicity has not been established. Meteorological conditions such as temperature and high relative humidity have been reported as important predictors of RSV epidemics [9,12]. In the United States (US) and Japan, annual national and regional variation of RSV season onset and end has been reported [13-15]. In the Nordic countries, a major outbreak often alternates with a minor one, with the minor peak in the spring and a major one the following winter [16-19], a phenomenon reported also in Croatia [20], Denmark [21] and Germany [22]. RSV antigenic groups A and B alternate in two-year cycles in Finland, with dominance of the group A viruses in years 1981–82, 1985–86 and 1989–90 and the group B viruses 1983–84 and 1987–88 [17,19], and different genotypes dominate the circulation in consecutive epidemics in Korea [23]. In Spain, no biennial rhythm has been detected but rather a stable annual epidemic with a peak between week 52 and week 1 and circulation 2–8 weeks earlier than influenza viruses [24]. Similarly, in the United Kingdom (UK), one stable epidemic per year is observed [5]. Immunoprophylaxis to prevent RSV infection with a neutralising monoclonal antibody, palivizumab, has been developed for administration to target groups on a monthly basis during the RSV season [25]. However, this drug is limited to high-risk infants, the cost prohibits its use in low- and middle-income countries and the data on effectiveness of the drug in children at high risk other than infants born at gestational age
Published: 2018

20. General Practitioners Perceptions About Financial and Non-Financial Incentives to Improve Influenza Vaccination Coverage Rates In France

Author: Hans-Martin Späth, Maria-Laura Silva, Jean Cohen, John Paget, Anne Mosnier, Valérie Buthion, M. Aulois-Griot, Lionel Perrier, Université de Bordeaux (UB), Centre Léon Bérard [Lyon], Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Netherlands Institute for Health Services Research, COnception de l'ACTIon en Situation (COACTIS), Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM), Organize and Promote Epidemiological Network (Open Rome), Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), COACTIS (COACTIS), Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), and Dao, Taï
Subjects: Actuarial science, business.industry, 030503 health policy & services, Health Policy, media_common.quotation_subject, Public Health, Environmental and Occupational Health, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, 3. Good health, electronic patient records, 03 medical and health sciences, 0302 clinical medicine, information system, Financial incentives, Perception, Vaccination coverage, Information system, Medicine, 030212 general & internal medicine, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, 0305 other medical science, business, ComputingMilieux_MISCELLANEOUS, media_common
Abstract: International audience
Published: 2016

21. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century

Author: John Paget, Olga Bessonova, Joseph S. Bresee, Norosoa Harline Razanajatovo, Saverio Caini, Binay Thapa, Francisco José de Paula Júnior, Jenny Lara Araya, Florette K. Treurnicht, Walquiria Aparecida Ferreira de Almeida, Brechla Moreno Arévalo, Zhibin Peng, Raquel Guiomar, Gabriela Kusznierz, Q. Sue Huang, Herman Kosasih, Antonino Bella, Doménica de Mora, Rakhee Palekar, Olha Holubka, Maria R. Castrucci, Rudevelinda Rivera, Phuong Vu Mai Hoang, Gideon O. Emukule, Rodrigo Fasce, Rocio Higueros, Sandra S. Chaves, Fatima el Falaki, Mai T. Q. Le, Herve A. Kadjo, Patricia Bustos, Luzhao Feng, Ainash Makusheva, Vernon J. Lee, Richard Njouom, Ana Paula Rodrigues, Coulibaly Daouda, Gé Donker, Alfredo Bruno, Alla Mironenko, Cheryl Cohen, Jean-Michel Heraud, Li Wei Ang, Sonam Wangchuk, Mónica Jeannette Barahona de Gámez, Maria Zambon, Clotilde El Guerche-Séblain, Angel Balmaseda, Lynnette Brammer, Amal Barakat, Richard Pebody, Adam Meijer, Verònica Vera Garate, Tim Wood, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto Nacional de Enfermedades Respiratorias Dr. Emilio Coni [Santa Fe, Argentina] (INER), Ministry of Health [Bhoutan], Ministry of Health [Brasília, Brazil], Centre Pasteur du Cameroun, Réseau International des Instituts Pasteur (RIIP), Instituto de Salud Pública de Chile (ISP), Chinese Center for Disease Control and Prevention, Ministry of Health [Costa Rica], Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud de El Salvador (MINSAL), Public Health England [London], Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), Ministry of Health [Honduras] (SESAL), US Naval Medical Research Unit No.2 [Jakarta, Indonesia] (NAMRU-2), Naval Medical Research Center [Silver Spring, USA] (NMRC), Istituto Superiore di Sanita [Rome], Institut Pasteur de Côte d'Ivoire, Institut National de Santé Publique d'Abidjan-INSP, Ministry of Healthcare [Kazakhstan], Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Centers for Disease Control and Prevention [Kenya], Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut National d'Hygiène [Maroc], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Institute of Environmental Science and Research (ESR), Ministry of Health [Nicaragua] (MINSA), Pan American Health Organization [Washington] (PAHO), Instituto Conmemorativo Gorgas de Estudios de la Salud [Panamá], Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Ministry of Health [Singapore], National Institute for Communicable Diseases [Johannesburg] (NICD), University of the Witwatersrand [Johannesburg] (WITS), National Academy of Sciences of Ukraine (NASU), National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Sanofi Pasteur [Lyon, France], The study is supported by a research grant from Sanofi Pasteur: the ‘Global Epidemiology of Influenza B’ research project. The funder provided support in the form of salaries for two authors (CEGS and JP) but did not have any additional role in the data collection, analysis, decision to publish, or preparation of the manuscript., The 'Global Influenza B Study team' (group authorship) includes the following scientists: Juan Manuel Rudi (jmrudi@anlis.gov.ar), National Institute of Respiratory Diseases 'Emilio Coni', Santa Fe, Argentina, Dorji Wangchuk (dorjiwangchuk@health.gov.bt) and Sangay Zangmo (szangmo@health.gov.bt), Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan, Daiana Araujo da Silva (daiana.silva@saude.gov.br), Ministry of Health, Department of Surveillance of Transmissible Diseases, Brasília/DF, Brazil, Winston Andrade (wandrade@ispch.cl), Sub-Department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile, Jiandong Zheng (zhengjd@chinacdc.cn) and Ying Qin (qinying@chinacdc.cn), Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China, Joanna Ellis (joanna.ellis@phe.gov.uk), Public Health England, London, United Kingdom, Simona Puzelli (simona.puzelli@iss.it), National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy, Caterina Rizzo (rizzocaterina@gmail.com), Bambino Gesù Children's Hospital, Rome, Italy, Linus Ndegwa (ikf7@cdc.gov), Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya, Marit MA de Lange (marit.de.lange@rivm.nl) and Anne C. Teirlinck (anne.teirlinck@rivm.nl), National Institute for Public Health and the Environment, Centre for Infectious Diseases, Epidemiology and Surveillance, Bilthoven, The Netherlands, Jeffery Cutter (jeffery_cutter@moh.gov.sg) and Raymond Tzer Pin Lin (raymond_lin@moh.gov.sg), Public Health Group, Ministry of Health, Singapore, Singapore, Than T. Le (lmot82@yahoo.com), National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, and Peter Kinuthia 42 (polorien@gmail.com), IHRC Inc., Atlanta, USA.
Subjects: RNA viruses, Male, Infecções Respiratórias, 0301 basic medicine, Viral Diseases, medicine.disease_cause, MESH: Influenza Vaccines, Seasonal influenza, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Epidemiology, Medicine and Health Sciences, Influenza A virus, 030212 general & internal medicine, MESH: Influenza B virus, Pathology and laboratory medicine, Northern Hemisphere, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Multidisciplinary, Geography, MESH: Influenza, Human, virus diseases, Medical microbiology, 3. Good health, Infectious Diseases, Influenza Vaccines, Population Surveillance, Viruses, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Medicine, Southern Hemisphere, Female, Age distribution, Seasons, Pathogens, MESH: History, 21st Century, Research Article, medicine.medical_specialty, Infectious Disease Control, Science, MESH: Influenza A virus, Biology, Microbiology, History, 21st Century, Virus, MESH: Population Surveillance, MESH: Influenza A Virus, H1N1 Subtype, 03 medical and health sciences, Age Distribution, Population Metrics, Influenza, Human, medicine, Influenza viruses, Humans, Epidemics, MESH: Epidemics, Disease burden, MESH: Humans, Biology and life sciences, Population Biology, Organisms, Viral pathogens, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Estados de Saúde e de Doença, Virology, Influenza, MESH: Male, Microbial pathogens, Earth sciences, Influenza B virus, Vaccine mismatch, 030104 developmental biology, Virus type, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Epidemiological Monitoring, Geographic areas, MESH: Seasons, MESH: Female, Orthomyxoviruses
Abstract: Free PMC article: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31513690/ We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000-2018. We calculated the proportion of cases caused by influenza B and its lineages; determined the timing of influenza A and B epidemics; compared the age distribution of B/Victoria and B/Yamagata cases; and evaluated the frequency of lineage-level mismatch for the trivalent vaccine. The median proportion of influenza cases caused by influenza B virus was 23.4%, with a tendency (borderline statistical significance, p = 0.060) to be higher in tropical vs. temperate countries. Influenza B was the dominant virus type in about one every seven seasons. In temperate countries, influenza B epidemics occurred on average three weeks later than influenza A epidemics; no consistent pattern emerged in the tropics. The two B lineages caused a comparable proportion of influenza B cases globally, however the B/Yamagata was more frequent in temperate countries, and the B/Victoria in the tropics (p = 0.048). B/Yamagata patients were significantly older than B/Victoria patients in almost all countries. A lineage-level vaccine mismatch was observed in over 40% of seasons in temperate countries and in 30% of seasons in the tropics. The type B virus caused a substantial proportion of influenza infections globally in the 21st century, and its two virus lineages differed in terms of age and geographical distribution of patients. These findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza. info:eu-repo/semantics/publishedVersion
Published: 2019

22. Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?

Author: Marietjie Venter, Juan Yang, Simona Puzelli, Antonino Bella, Joshua A. Mott, Rodrigo Fasce, Coulibaly Daouda, Jenny Lara, Hongjie Yu, Winston Andrade, Selim Badur, Cláudio Maierovitch Pessanha Henriques, François G. Schellevis, Jean-Michel Heraud, Akerke Ospanova, Sonam Wangchuk, Brechla Moreno, Herve A. Kadjo, Raymond T. P. Lin, Juan Manuel Rudi, Walquiria Aparecida Ferreira de Almeida, Gabriela Kusznierz, Joseph S. Bresee, Cheryl Cohen, Mai thi Quynh Le, Rhonda Owen, Maria Zambon, Maria Luisa Matute, Kunzang Dorji, Kate Pennington, Global Influenza B Study, Herman Kosasih, Nurhayati, Alla Mironenko, Ming Li, Angel Balmaseda, Alexey Clara, Alfredo Bruno, Richard Njouom, Phuong Vu Mai Hoang, Ana Paula Rodrigues, Celina de Lozano, Luzhao Feng, Olha Holubka, Amal Barakat, Lyazzat Kiyanbekova, Norosoa Harline Razanajatovo, Saverio Caini, Meral Akcay Ciblak, Raquel Guiomar, Richard Pebody, Leticia Castillo, Gideon O. Emukule, Liza Lopez, Doménica de Mora, Jeffery Cutter, Q. Sue Huang, Marie-Astrid Vernet, Abderrahman Bimohuen, John Paget, Lynnette Brammer, General practice, EMGO - Quality of care, Netherlands Institute for Health Services Research, Instituto de Salud Pública de Chile (ISP), Istanbul University, Ministry of Health [Nicaragua] (MINSA), Ministry of Health [Morocco], Istituto Superiore di Sanita [Rome], Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), US Centers for Disease Control, University of the Witwatersrand [Johannesburg] (WITS), Ministry of Health, Institut Pasteur de Côte d'Ivoire, Réseau International des Instituts Pasteur (RIIP), Ministerio de Salud de El Salvador (MINSAL), Ministry of Health [Bhoutan], US Centers for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Instituto nacional de saude, Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), National Academy of Medical Sciences of Ukraine, Institute of Environmental Science and Research (ESR), Astana Center of Sanitary Epidemiology Expertise, US Naval Medical Research Unit n°2, Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni', Ministry of Health [Costa Rica], National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Ministry of Health [Honduras] (SESAL), National Influenza Center, Centre Pasteur du Cameroun, Office of Health Protection, Woden, ACT, Australia (DHAISS), Public Health England [London], National Institute of Health, University of Pretoria [South Africa], The Global Influenza B Study is supported by an unrestricted research grant from Sanofi Pasteur. The study sponsor had no role in the design of the study, in the collection, analysis, and interpretation of data, in the writing of the report, and and in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study sponsor had no access to the data in the study.
Subjects: Infecções Respiratórias, Influenza Viruses, Epidemiology, Gripe, Pathology and Laboratory Medicine, Geographical locations, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, DRIVERS, Estados de Saúde, Public and Occupational Health, SUB-SAHARAN AFRICA, lcsh:Science, MESH: Influenza B virus, Northern Hemisphere, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Geography, MESH: Influenza, Human, Vaccination, virus diseases, 3. Good health, Global Influenza B Study, MESH: Tropical Climate, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Science & Technology - Other Topics, Immunology, Disease Surveillance, SEASONAL INFLUENZA, Microbiology, Influenza Vaccin, 03 medical and health sciences, Influenza Vaccination, SURVEILLANCE, Humans, Microbial Pathogens, Retrospective Studies, MESH: Humans, Science & Technology, lcsh:R, Organisms, Correction, Influenza a, MESH: Retrospective Studies, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, Virology, Influenza, MADAGASCAR, lcsh:Q, Preventive Medicine, People and places, Demography, RNA viruses, Viral Diseases, lcsh:Medicine, medicine.disease_cause, Tropical climate, Medicine and Health Sciences, Influenza A virus, 030212 general & internal medicine, Multidisciplinary, Medical microbiology, Vaccination and Immunization, Multidisciplinary Sciences, Infectious Diseases, Viruses, Human mortality from H5N1, Southern Hemisphere, Seasons, Pathogens, Brazil, Research Article, Infectious Disease Control, General Science & Technology, 030231 tropical medicine, MESH: Influenza A virus, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], MD Multidisciplinary, Influenza, Human, Temperate climate, medicine, Tropical Climate, Biology and life sciences, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Viral pathogens, Tropics, MESH: Vaccination, South America, Seasonality, Earth sciences, Influenza B virus, Infectious Disease Surveillance, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Geographic areas, MESH: Seasons, Orthomyxoviruses
Abstract: Erratum in - Correction: Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination? PLoS One. 2016 May 2;11(5):e0155089. doi: 10.1371/journal.pone.0155089. Introduction: Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed the temporal characteristics of influenza epidemics in the Northern and Southern hemispheres and in the tropics, and discuss their implications for vaccination programmes. Methods: This was a retrospective analysis of surveillance data between 2000 and 2014 from the Global Influenza B Study database. The seasonal peak of influenza was defined as the week with the most reported cases (overall, A, and B) in the season. The duration of seasonal activity was assessed using the maximum proportion of influenza cases during three consecutive months and the minimum number of months with 80% of cases in the season. We also assessed whether co-circulation of A and B virus types affected the duration of influenza epidemics. Results: 212 influenza seasons and 571,907 cases were included from 30 countries. In tropical countries, the seasonal influenza activity lasted longer and the peaks of influenza A and B coincided less frequently than in temperate countries. Temporal characteristics of influenza epidemics were heterogeneous in the tropics, with distinct seasonal epidemics observed only in some countries. Seasons with co-circulation of influenza A and B were longer than influenza A seasons, especially in the tropics. Discussion: Our findings show that influenza seasonality is less well defined in the tropics than in temperate regions. This has important implications for vaccination programmes in these countries. High-quality influenza surveillance systems are needed in the tropics to enable decisions about when to vaccinate. The Global Influenza B Study is supported by an unrestricted research grant from Sanofi Pasteur. info:eu-repo/semantics/publishedVersion
Published: 2016

23. Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants

Author: John Paget, Jean Cohen, Hans-Martin Späth, Valérie Buthion, Anne Mosnier, Maria-Laura Silva, Lionel Perrier, Centre Léon Bérard [Lyon], Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Netherlands Institute for Health Services Research, Open Rome, COACTIS (COACTIS), Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Laboratoire Coactis, COACTIS, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), and Organize and Promote Epidemiological Network (Open Rome)
Subjects: media_common.quotation_subject, 030231 tropical medicine, Declaration, [SHS]Humanities and Social Sciences, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public Health, Interviews as Topic, 03 medical and health sciences, Interviews, 0302 clinical medicine, Voting, Qualitative research, Influenza, Human, Humans, Medicine, 030212 general & internal medicine, Policy Making, Health policy, ComputingMilieux_MISCELLANEOUS, Netherlands, media_common, business.industry, Policy-making, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Administrative Personnel, Public relations, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, NITAG, 3. Good health, Vaccination, Vaccination policy, Influenza Vaccines, Transparency (graphic), Human influenza, [SHS] Humanities and Social Sciences, France, Thematic analysis, business, Vaccination recommendations
Abstract: Item does not contain fulltext OBJECTIVES: Target groups for seasonal influenza vaccination are nationally defined based on several factors. However, few studies have explored the policy-making processes at the country-level. We investigated key differences in the policy-making process for the development of vaccination recommendations between France (FR) and The Netherlands (NL). This paper presents preliminary results on the evidence used in the decision-making process and focuses on the interactions between the experts and stakeholders. METHODS: A documentary analysis identified the stakeholders of this process as governmental authorities, research institutions, associations, and manufacturers. This qualitative study included at least one expert from each stakeholder group. Thirty-three semi-structured interviews were performed in 2013 (16 FR, 17 NL). We used NVivo10(R) to perform a thematic content analysis on the data. RESULTS: National Immunization Technical Advisory Groups (NITAGs) were the key stakeholders in the development of recommendations. There was no systematic standard evaluation of evidence during the decision-making process in both countries. Likewise, voting was not systematic, although it did occur more often in FR. A declaration of interests was obligatory in both countries. Experts with no conflicts of interest were rare because many depend on private funding for their research on influenza vaccination. CONCLUSIONS: The transparency of the NITAGs' procedures for the development of recommendations should be improved. We believe improvements might be achieved by the systematic standard evaluation of evidence, consistent voting, clear declarations of interest, and increased public funding for vaccination research.
Published: 2016

24. Development of Seasonal Influenza Vaccination Recommendations: Relevance and Influence of the Evidence on the Decision-Making Process in France and the Netherlands

Author: Maria-Laura Silva, Lionel Perrier, Jean Cohen, Hans-Martin Späth, Valérie Buthion, Anne Mosnier, John Paget, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Netherlands Institute for Health Services Research, Organize and Promote Epidemiological Network (Open Rome), COnception de l'ACTIon en Situation (COACTIS), Université Lumière - Lyon 2 (UL2)-Université Jean Monnet - Saint-Étienne (UJM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), COACTIS (COACTIS), Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, media_common.quotation_subject, 030231 tropical medicine, Guidelines as Topic, decision making, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Environmental health, Epidemiology, Influenza, Human, medicine, Relevance (law), Humans, Quality (business), 030212 general & internal medicine, Decision-making, ComputingMilieux_MISCELLANEOUS, media_common, Netherlands, Protocol (science), business.industry, Health Policy, Vaccination, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Public Health, Environmental and Occupational Health, Public relations, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, NITAG, influenza vaccination, 3. Good health, Economic model, Female, France, Seasons, Thematic analysis, business, qualitative research, Qualitative research
Abstract: Item does not contain fulltext BACKGROUND: Target groups for seasonal influenza vaccination are defined at the country level and are based on several factors. However, little is known about the national decision-making procedures. OBJECTIVE: The purpose of this study was to compare the evidence used for the development of recommendations and its impact on the choice of target groups in France and the Netherlands. METHODS: A preliminary documentary analysis identified institutions to include in the assessment: governmental authorities, research institutions, associations, and manufacturers. At least one expert from each group was invited to our study. Thirty-three semi-structured interviews were conducted in 2013 (16 France, 17 the Netherlands). We used NVivo10(R) to perform a thematic content analysis. RESULTS: Clinical/epidemiological studies were the evidence most used in both countries. Economic models were increasingly being used; these had greater influence on the decision making in the Netherlands than in France, probably because of the presence of a modeler. Generally, the quality of the evidence used was poor, although no systematic use of standard protocol for its assessment was observed. A general protocol was sometimes used in France; however, the personal judgment of the experts was crucial for the assessment in both countries. CONCLUSIONS: There were differences in the target groups, for example, pregnant women, recommended only in France. France and the Netherlands use similar evidence for developing vaccination recommendations, although different decisions are sometimes made regarding target groups. This could be associated with the lack of systematic standard appraisals, increasing the influence of the experts' judgment on decision making. The development of standards for the appraisal of evidence is recommended.
Published: 2016

25. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season

Author: Meijer, Adam, Lackenby, Angie, Hungnes, Olav, Lina, Bruno, Van Der Werf, Sylvie, Schweiger, Brunhilde, Opp, Matthias, Paget, John, Van-De-Kassteele, Jan, Hay, Alan, Zambon, Maria, Surveillance Scheme, On Behalf Of The European Influenza, Netherlands Institute for Health Services Research, National Institute for Public Health and the Environment [Bilthoven] (RIVM), European Surveillance Network for Vigilance against Viral Resistance, Health Protection Agency, Norwegian Institute of Public Health [Oslo] (NIPH), Centre National de Référence Virus Influenza (Région Sud), Hospices Civils de Lyon (HCL), Centre National de Référence de la Grippe (France Nord) - Centre Collaborateur de l'OMS Grippe et autres virus respiratoires (CNR - CCOMS), Institut Pasteur [Paris], Robert Koch Institute [Berlin] (RKI), Laboratoire National de Santé [Luxembourg] (LNS), World Health Organization Collaborating Centre Medical Research Council/National Institute of Medical Research, and Institut Pasteur [Paris] (IP)
Subjects: Microbiology (medical), Genes, Viral, oseltamivir, Epidemiology, viruses, Hemagglutinins, Viral, Neuraminidase, Antiviral Agents, Communicable Diseases, Emerging, 03 medical and health sciences, Influenza A Virus, H1N1 Subtype, Drug Resistance, Viral, Influenza, Human, Humans, influenza A virus, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, antimicrobial resistance, Enzyme Inhibitors, Phylogeny, 030304 developmental biology, 0303 health sciences, 030306 microbiology, Research, H1N1, virus diseases, 3. Good health, Europe, Infectious Diseases, Population Surveillance, Mutation, surveillance, Seasons
Abstract: A high level of virus circulation and introduction of an antigenic drift variant in a susceptible population contributed to the spread of resistant virus., In Europe, the 2007–08 winter season was dominated by influenza virus A (H1N1) circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant influenza viruses A (H1N1) (ORVs) with H275Y mutation in the neuraminidase emerged independently of drug use. By country, the proportion of ORVs ranged from 0% to 68%, with the highest proportion in Norway. The average weighted prevalence of ORVs across Europe increased gradually over time, from near 0 in week 40 of 2007 to 56% in week 19 of 2008 (mean 20%). Neuraminidase genes of ORVs possessing the H275Y substitution formed a homogeneous subgroup closely related to, but distinguishable from, those of oseltamivir-sensitive influenza viruses A (H1N1). Minor variants of ORVs emerged independently, indicating multiclonal ORVs. Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.
Published: 2009

26. New directions in European public health research

Author: Aileen Clarke, Mark I. McCarthy, Selma Šogorić, Peter P. Groenewegen, Wim Groot, Carlos Álvarez-Dardet, Diana M. J. Delnoij, Universidad de Alicante. Departamento de Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia, Public Health Resource Unit (Oxford), University College, London. Department of Epidemiology and Public Health, University of Zagreb. Andrija Stampar School of Public Health, Netherlands Institute for Health Services Research, Maastricht University. Department of Health Sciences, and Salud Pública
Subjects: medicine.medical_specialty, Epidemiology, Public policy, Environmental health, Medicine, Humans, Health policy, HRHIS, Evidence-Based Medicine, business.industry, Public health research, Public health, INCOME INEQUALITY, Health Policy, European study, Public Health, Environmental and Occupational Health, Health services research, International health, Public relations, Europe, Health promotion, Research Design, Community health, Medicina Preventiva y Salud Pública, Health Services Research, Public Health, business, Decision making, Evidence Based Public Health Policy and Practice, Public Health Administration, Needs Assessment, public heatlj, research
Abstract: Public health draws from a range of academic disciplines, social, medical and statistical, and answers questions relevant to improving the health of populations. We have initiated a Europe-wide study, Strengthening Public Health Research in Europe, to assess the development and use of public health research in both public policy and local decision making. The contemporary challenge for public health research is to integrate the capabilities of different academic disciplines to address policies for health. We have considered the development of public health research in five fields: political epidemiology, community health, health services, economics, and evaluation evidence and synthesis. The organisation and funding of research in Europe should be able to support new research fields and issues, to contribute to policy development and public health practice. European Union.
Published: 2007

27. A literature review to identify factors that determine policies for influenza vaccination

Author: Lionel Perrier, Anne Mosnier, Jean Cohen, Maria-Laura Silva, Hans-Martin Späth, William John Paget, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Centre Léon Bérard [Lyon], Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, NIVEL, Netherlands Institute for Health Services Research, Institut des Sciences Pharmaceutiques et Biologiques (ISPB), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Context (language use), Disease, Influenza, Human, Pandemic, Humans, Relevance (law), Medicine, Policy Making, ComputingMilieux_MISCELLANEOUS, Decision Making, Organizational, Qualitative Research, Health policy, business.industry, Policy-making, Health Policy, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Vaccination, Public relations, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Checklist, Influenza vaccination, 3. Good health, Vaccination policy, Influenza Vaccines, business, Decision-making, Qualitative research
Abstract: Item does not contain fulltext OBJECTIVES: To conduct a literature review of influenza vaccination policy, describing roles and interactions between stakeholders and the factors influencing policy-making. METHODS: Major databases were searched using keywords related to influenza vaccination, decision-making and healthpolicy. Titles and abstracts were screened according to defined criteria using independent reviewers. Selected articles were analysed and compared against a checklist. RESULTS: 342 papers were identified, but only 111 included. A wide range of countries was represented in articles published in 1994-2012. We identified numerous stakeholders at the national and international level and found a variety of interactions between them. Using these data, we suggest a scheme for the most important stakeholders and their interactions. Determinants of policy-making were mainly related to the vaccine/disease, political-economic context, and stakeholders communication. The most relevant evidence was clinical/epidemiological studies. After the 2009 pandemic: the importance of mathematical modelling and ethical issues was greater; and the need for better communication between stakeholders was emphasised. CONCLUSIONS: The relevance of evidence and factors influencing policy-making varied between countries, according to complex interactions between the stakeholders involved at different levels of decision-making process. These interactions remain unclear, especially at national level, where the most important influenza policy decisions are made. To better define and understand the exact interactions and use of evidence, we recommend undertaking future qualitative studies at national level using small number of countries.
Published: 2015

28. Literature review of the decision-‐making determinants related to the influenza vaccination policy

Author: Hans-Martin Späth, Lionel Perrier, John Paget, Anne Mosnier, Jean Cohen, Maria-Laura Silva, Centre Léon Bérard [Lyon], Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, Netherlands Institute for Health Services Research, Santé Individu Société - SIS (SIS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2), Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Santé Individu Société (SIS), Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), and Dao, Taï
Subjects: Population, Context (language use), Scientific evidence, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public Health, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Pandemic, Medicine, 030212 general & internal medicine, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, education, Health policy, public health policy, education.field_of_study, 030505 public health, Actuarial science, business.industry, decision-making, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Checklist, influenza vaccination, 3. Good health, Vaccination, decision-making,influenza vaccination,public health policy, Vaccination policy, 0305 other medical science, business
Abstract: Background : Seasonal influenza concerns the worldwide population every year, whilst pandemic influenza is an unpredictable threat. Due to an important socioeconomic impact, mitigation measures must be specified. Governments elaborate vaccination policy based on scientific evidence. However, this process is, in general, not transparent. Objectives : To study the decision-making process related to the influenza vaccination policy, identifying the actors involved, the decisions made and describing the information used by type and level of importance. Methods : Six major databases were searched in seven languages, without time limit, using keywords related to influenza vaccination, decision-making and health policy. Titles and abstracts were screened according to three established criteria. Selected articles were analysed and compared against a checklist for context, stakeholders and evidence. Results : 111 articles were retrieved since the 1990s, most of them (40%) were conducted in the USA. The decision-making process mainly concerned vaccination strategies (53%) and pandemic preparedness (28%). Stakeholders were identified at an institutional, production and consumer level. Evidence used by policy-makers was similar (e.g. logistics of vaccines), but the factors influencing were different (e.g. social conditions). Conclusion : Considering the imminent risk of socio-economic disruption and media pressure, the pandemic threat needs to be integrated into an analysis of decision making processes regarding seasonal influenza vaccination.
Published: 2013

29. IBGP : Étude Européenne du fardeau de la grippe B en médecine ambulatoire

Author: Silva, Maria-Laura, Fleming, Douglas, Mosnier, Anne, Daviaud, Isabelle, Bui, Tan Taï, Paget, John, Cohen, Jean Marie, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Réseau des Groupes Régionaux d'Observation de la Grippe (GROG), Coordination nationale, Netherlands Institute for Health Services Research, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), and Dao, Taï
Subjects: Europe, Surveillance, General Practice, Influenza B, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Published: 2012

30. Prescribing patterns for upper respiratory tract infections in general practice in France and in the Netherlands

Author: Pascal Clerc, Marc Le Vaillant, Nathalie Pelletier-Fleury, Sophia Rosman, François G Schellevis, Robert A Verheij, General practice, EMGO - Quality of care, CERMES - Centre de recherche Médecine, Science, Santé Société (CERMES - UMR 8169 / U750), Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), VU University Medical Center [Amsterdam], Société française de médecine générale, Issy les Moulineaux, and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)
Subjects: Adult, Cross-Cultural Comparison, Male, medicine.medical_specialty, Pediatrics, Adolescent, Physician's Practice Patterns, Patient characteristics, Logistic regression, Drug Prescriptions, Antibiotic prescribing, [SHS]Humanities and Social Sciences, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Internal medicine, medicine, Humans, 030212 general & internal medicine, Practice Patterns, Physicians', Medical diagnosis, Medical prescription, Medical patient, Respiratory Tract Infections, Netherlands, 0303 health sciences, Analgesics, Respiratory tract infections, 030306 microbiology, business.industry, Public Health, Environmental and Occupational Health, Age Factors, Middle Aged, Drug Utilization, 3. Good health, Anti-Bacterial Agents, Tonsillitis, General practice, Female, France, Guideline Adherence, business, Family Practice
Abstract: International audience; Background : France and the Netherlands are often presented as two contrasting countries with regard to drug prescriptions and consumption. This study Aim :ed to analyse general practitioners' (GP's) prescription patterns for upper respiratory tract infections (URTI). METHODS: Data on diagnoses and prescriptions were derived from two databases recording daily electronic medical patient files: the 'Société Française de Médecine Générale' database (SFMG-DB) and the Dutch Landelijk Informatie Netwerk Huisatsenzorg database (LINH-DB). Logit regression models were developed to estimate and compare prescription patterns in both countries. We carried out a study including all the patients consulting for URTI in 2003. RESULTS: French GPs had more URTI patients than their Dutch counterparts (372.1 URTI patients/GP versus 181.3). They prescribed higher volumes of URTI medications (3.55 per patient/year versus 0.82). Striking differences were observed in analgesic and symptomatic prescriptions (0.84 per patient/year versus 0.12 and 1.01 per patient/year versus 0.21, respectively). We did not observe important discrepancies in volume of antibiotic prescriptions (0.29 per patient/year in France versus 0.32). After adjustment for patient characteristics, the logit model showed that prescription patterns for antibiotic were quite similar and associated with a diagnosis of acute tonsillitis. CONCLUSION: The analysis per consultation in this study did not highlight important differences in antibiotic prescribing volumes and patterns. But symptomatic and analgesic prescriptions were significantly higher in the French database. This can be explained by differences in help-seeking behaviour, medication perception, status of OTC medications and remuneration system.
Published: 2008

31. Does disaster affect immigrant victims more than non-immigrant victims in Dutch general practice: a matched cohort study

Author: Jouke van der Zee, Wil van den Bosch, Rik J. H. Soeteman, Jan J. Kerssens, C. Joris Yzermans, Tina Dorn, Peter Spreeuwenberg, NIVEL, Netherlands Institute for Health Services Research, Department of General Practice, and Radboud University Medical Center [Nijmegen]
Subjects: medicine.medical_specialty, Turkish, media_common.quotation_subject, Immigration, education, Disasters, Ethnicity, Morbidity, Longitudinal studies, General practice, Ethnic group, Indigenous, Epidemiology, Medicine, ddc:610, Medicine, Social Medicine, Psychiatry, Migration, Sociology of Migration, Socioeconomic status, Social sciences, sociology, anthropology, ComputingMilieux_MISCELLANEOUS, health care economics and organizations, Migration, media_common, Sozialwissenschaften, Soziologie, Medizin und Gesundheit, business.industry, Public health, Public Health, Environmental and Occupational Health, social sciences, language.human_language, humanities, Medizin, Sozialmedizin, Medicine and health, language, behavior and behavior mechanisms, International Classification of Primary Care, ddc:300, business
Abstract: Background: In the literature, immigrant victims appear to be more vulnerable to health effects of a disaster than indigenous victims. Most of these studies were performed without pre-disaster measurement and without using a control group. Aim: The objective of the study is to monitor differences between two groups of victims, Turkish immigrants and indigenous Dutch, in utilization and morbidity as presented in general practice after a man-made disaster. Methods: A matched cohort study was performed with pre-disaster (1 year) and post-disaster (4 years) measurements of patients from 30 general practices in Enschede. Turkish victims (N=303) and Dutch victims (N=606), matched on age, gender and socioeconomic status, were included. Main outcome measures were psychological problems and physical symptoms as recorded by the general practitioner, using the International Classification of Primary Care (ICPC). Results: The Turkish victims showed higher utilization than the Dutch victims prior to the disaster. In the 1st post-disaster year, both groups of victims showed an increase in utilization, but the increases did not differ significantly. The Turkish group showed no significantly greater increase than the Dutch group in the five most prevalent clusters of health problems (psychological, respiratory, skin, musculoskeletal, and digestive). Conclusion: The Turkish victims in general practice were as vulnerable as the Dutch victims for the effects on their health of this man-made disaster. Differences between Turkish and native Dutch victims of this man-made disaster can largely be explained by the differences that existed already before the disaster.
Published: 2008

32. Community engagement and vulnerability in infectious diseases: A systematic review and qualitative analysis of the literature

Author: Ruth Kutalek, Tamara Giles-Vernick, John Paget, Michel L. A. Dückers, Christos Baliatsas, David Napier, Jacob Osborne, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Anthropologie et écologie de l’émergence des maladies - Anthropology and Ecology of Disease Emergence, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Medizinische Universität Wien = Medical University of Vienna, University College of London [London] (UCL), ARQ National Psychotrauma Centre [Diemen, the Netherlands], and University of Groningen [Groningen]
Subjects: Health (social science), media_common.quotation_subject, Vulnerability, Global health, Context (language use), Trust, Communicable Diseases, [SHS]Humanities and Social Sciences, 03 medical and health sciences, Racism, 0302 clinical medicine, History and Philosophy of Science, Humans, 030212 general & internal medicine, Sociology, 10. No inequality, Empowerment, Interventions, media_common, Medical Assistance, 030505 public health, Local history, Community engagement, business.industry, Participation, Community Participation, Public relations, 3. Good health, Variety (cybernetics), Government Programs, Framing (social sciences), Infectious diseases, Intersectoral Collaboration, 0305 other medical science, business
Abstract: International audience; The global response to infectious diseases has seen a renewed interest in the use of community engagement to support research and relief efforts. From a perspective rooted in the social sciences, the concept of vulnerability offers an especially useful analytical frame for pursuing community engagement in a variety of contexts. However, few have closely examined the concept of vulnerability in community engagement efforts, leading to a need to better understand the various theories that underline the connections between the two. This literature review searched four databases (covering a total of 537 papers), resulting in 15 studies that analyze community engagement using a framing of vulnerability, broadly defined, in the context of an infectious disease, prioritizing historical and structural context and the many ways of constituting communities. The review identified historical and structural factors such as trust in the health system, history of political marginalization, various forms of racism and discrimination, and other aspects of vulnerability that are part and parcel of the main challenges faced by communities. The review found that studies using vulnerability within community engagement share some important characteristics (e.g., focus on local history and structural factors) and identified a few theoretical avenues from the social sciences which integrate a vulnerability-informed approach in community engagement. Finally, the review proposes an approach that brings together the concepts of vulnerability and community engagement, prioritizing participation, empowerment, and intersectoral collaboration.
Full Text: View/download PDF

33. Recommendations for respiratory syncytial virus surveillance at the national level

Author: Janine Reiche, Harish Nair, Raquel Guiomar, Manuel Gijon, Kostas Danis, Håkon Bøås, Martina Havlíčková, Joanne O Gorman, Bruno Lina, Marie Rapp, Hanne-Dorthe Emborg, Rachel M Reeves, Eeva Broberg, Ramona Trebbien, AnnaSara Carnahan, Anne C. Teirlinck, Gatis Pakarna, Sylvie van der Werf, Siddhivinayak Hirve, Hanna Nohynek, Silke Buda, Are Stuwitz Berg, Maja Socan, Jesus Angel Oliva, Thea Kølsen Fischer, Harry Campbell, Adam Meijer, Karol Szymanski, John Paget, National Institute for Public Health and the Environment [Bilthoven] (RIVM), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Norwegian Institute of Public Health [Oslo] (NIPH), University of Edinburgh, Public Health Agency of Sweden, Hospices Civils de Lyon (HCL), Université de Lyon, Riga East University Hospital, National Institute for Health and Welfare [Helsinki], Statens Serum Institut [Copenhagen], Robert Koch Institute [Berlin] (RKI), Instituto de Salud Carlos III [Madrid] (ISC), Health Protection Surveillance Centre (HPSC), Netherlands Institute for Health Services Research [Utrecht] (NIVEL), National Institute of Public Health - National Institute of Hygiene [Poland], Santé publique France - French National Public Health Agency [Saint-Maurice, France], National Institute of Public Health, Ljubljana, Slovenia, Penta [Padova], National Institute of Public Health [Prague], Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Virologie (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Nordsjællands Hospital [Hillerød, Denmark], and University of Southern Denmark (SDU)
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, [SDV]Life Sciences [q-bio], MEDLINE, Respiratory Syncytial Virus Infections, Virus, Epidemiology, medicine, media_common.cataloged_instance, Humans, National level, European union, Intensive care medicine, Child, Respiratory Tract Infections, media_common, Aged, Respiratory tract infections, business.industry, Public health, Respiratory infection, Infant, Hospitalization, Child, Preschool, Respiratory Syncytial Virus, Human, Task Force Report, business, Sentinel Surveillance
Abstract: Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections and hospitalisations among young children and is globally responsible for many deaths in young children, especially in infants aged, Recommendations for developing a feasible and sustainable national surveillance strategy for respiratory syncytial virus that will enable harmonisation and data comparison at the European level. https://bit.ly/3rWUOOI
Full Text: View/download PDF

34. Correction to: Psychosocial factors associated with quality of life in cancer survivors: umbrella review.

Author: Voskanyan V, Marzorati C, Sala D, Grasso R, Pietrobon R, van der Heide I, Engelaar M, Bos N, Caraceni A, Couspel N, Ferrer M, Groenvold M, Kaasa S, Lombardo C, Sirven A, Vachon H, Velikova G, Brunelli C, Apolone G, and Pravettoni G
Published: 2024
Full Text: View/download PDF

35. Potentially Inappropriate Medication in Older Persons With Dementia: Does a Migration Background Matter?

Author: Strooij BT, Blom MT, van Hout HPJ, Maarsingh OR, Elders PJM, van Campen JPCM, van der Heide I, Verheij RA, and Joling KJ
Subjects: Humans, Male, Female, Netherlands, Aged, Aged, 80 and over, Cohort Studies, Inappropriate Prescribing statistics & numerical data, Electronic Health Records, Dementia drug therapy, Potentially Inappropriate Medication List statistics & numerical data
Abstract: Objectives: Previous research in the general population shows more potentially inappropriate medications (PIMs) among persons with a migration background compared with persons without a migration background. This study investigated the association between non-Western (nw) migration background (MB) and dementia-specific PIMs in older adults with dementia in the Netherlands., Design: Cohort study using routinely recorded electronic health records and administrative data., Setting and Participants: Electronic health record data of general practitioners from the NIVEL-Primary Care Database, were linked to registries managed by Statistics Netherlands (2013-2014). A total of 9055 community-dwelling older adults with dementia were included, among whom 294 persons had an nw-MB from Africa, South America, or Asia, based on their country of birth., Methods: We determined the presence of dementia-specific PIM prescriptions and compared this between persons with an nw-MB and without an MB, using logistic regression analysis adjusted for follow-up time, age, registered sex, and total number of prescriptions. Interaction effects of potentially relevant covariates were tested. The 3 largest nw-MB groups in the Netherlands were analyzed separately., Results: Dementia-specific PIMs were less frequently prescribed to persons with an nw-MB compared to persons without an MB with a dementia diagnosis [30.6% vs 34.4%, odds ratio (OR) 0.71, 95% CI 0.54-0.92], with especially less often a benzodiazepine prescription in the group with an nw-MB, compared to persons without an MB (15.0% vs 19.3%, OR 0.61, 95% CI 0.43-0.84). Dementia duration, living alone, household income, and degree of urbanization did not influence the associations., Conclusions and Implications: Among older adults with dementia in the Netherlands, persons with an nw-MB had less often a dementia-specific PIM prescription compared to persons without an MB. Whether this difference is a reflection of better quality of care, higher professional uncertainty, or less recognition of (mental) health problems in persons with an nw-MB and dementia, needs further investigation., Competing Interests: Disclosures The authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

36. Pharmacists' current and potential prescribing roles in primary care in the Netherlands: a case study.

Author: Kempen TGH, Benaissa Y, Molema H, Valk LE, Hazen ACM, Heringa M, Kwint HF, Zwart DLM, Kälvemark Sporrong S, Stewart D, and van Dijk L
Subjects: Humans, Netherlands, Drug Prescriptions, Community Pharmacy Services organization & administration, Female, Male, Interviews as Topic, Cooperative Behavior, Interprofessional Relations, General Practice organization & administration, Practice Patterns, Pharmacists', Primary Health Care organization & administration, Pharmacists organization & administration, Professional Role
Abstract: In some countries, pharmacists have obtained prescribing rights to improve quality and accessibility of care and reduce physician workload. This case study explored pharmacists' current roles in and potential for prescribing in primary care in the Netherlands, where prescribing rights for pharmacists do not exist. Participatory observations of pharmacists working in either general practice or community pharmacy were conducted, as were semi-structured interviews about current and potential practice. The latter were extended to patients and other healthcare professionals, mainly general practitioners, resulting in 34 interviews in total. Thematic analyses revealed that pharmacists, in all cases, wrote prescriptions that were then authorized by a physician before dispensing. General practice-based pharmacists often prescribed medications during patient consultations. Community pharmacists mainly influenced prescribing through (a) medication reviews where the physician and/or practice nurse often were consulted to make treatment decisions, and (b) collaborative agreements with physicians to start or substitute medications in specific situations. These findings imply that the pharmacists' current roles in prescribing in the Netherlands resemble collaborative prescribing practices in other countries. We also identified several issues that should be addressed before formally introducing pharmacist prescribing, such as definitions of tasks and responsibilities and prescribing-specific training for pharmacists.
Published: 2024
Full Text: View/download PDF

37. Influenza vaccination and COVID-19 infection risk and disease severity: A systematic review and multilevel meta-analysis of prospective studies.

Author: Del Riccio M, Caini S, Bonaccorsi G, Lorini C, Paget J, van der Velden K, and Cosma C
Subjects: Humans, Prospective Studies, Vaccination statistics & numerical data, SARS-CoV-2, Severity of Illness Index, COVID-19 prevention & control, COVID-19 mortality, COVID-19 epidemiology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Influenza, Human mortality, Influenza, Human epidemiology, Hospitalization statistics & numerical data
Abstract: Background: In light of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, the influence of influenza vaccination on the risk and severity of Coronavirus Disease 19 (COVID-19) has been a subject of debate. This systematic review and meta-analysis of prospective studies aim to assess the association between influenza immunization and the risk of SARS-CoV-2 infection and subsequent COVID-19 disease severity., Methods: A comprehensive search of PubMed and Embase databases was performed to identify prospective studies published before March 2024. We focused on evaluating the effect of influenza vaccination on SARS-CoV-2 infection risk and severe COVID-19 outcomes, such as hospitalization and mortality. The analysis employed a multilevel random effects meta-analysis approach. The risk of bias assessment was conducted using the Newcastle-Ottawa Scale., Results: From an initial pool of 5,863 records, 14 studies were selected for inclusion. The aggregated data yielded a summary relative risk (SRR) that showed no significant protective correlation between influenza vaccination and SARS-CoV-2 infection risk (SRR 0.95, 95% confidence interval [CI] 0.81-1.11), COVID-19-associated hospitalization (SRR 0.90, 95% CI 0.68-1.19), or COVID-19-related mortality (SRR 0.83, 95% CI 0.56-1.23)., Conclusions: This systematic review and meta-analysis, based exclusively on prospective studies, demonstrates the lack of a proven protective effect of influenza vaccination against COVID-19 and related outcomes. Our results do not support a significant protective effect of influenza vaccination against the risk or severe outcomes of COVID-19., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

38. Citizens' perspectives on relocating healthcare.

Author: Damen LJ, De Jong JD, Van Tuyl LHD, and Korevaar JC
Subjects: Humans, Male, Female, Middle Aged, Netherlands, Adult, Aged, Surveys and Questionnaires, Delivery of Health Care
Abstract: Background: Healthcare systems around the globe are facing challenges. There are increasing demands and costs at the same time as a diminishing health workforce. Without change, healthcare will become unsustainable. The Dutch government is searching for solutions, one of which is relocating healthcare. Relocating healthcare from expensive institutions to sites closer to patients' homes is an important part of this. This relocation is expected to reduce costs and lessen shortages of personnel. However, although citizens have an important stake in this, little is known about how they think about this topic. This research aims at investigating citizens' perspectives on relocating care., Methods: In December 2021, three open-ended questions were sent to 1,500 members of Nivel's Dutch Healthcare Consumer Panel, 796 respondents responded. In addition, two citizen platforms were organised in March and April 2022. A total of 23 citizens participated., Results: Our results indicated that the following aspects are important for citizens in healthcare delivery: being treated by someone with expertise in the area of their need, familiarity with the healthcare provider and the treatment of less complex care close to home. When certain conditions are met, citizens prefer treatment for less complex care from their general practitioner rather than in a hospital. The most important condition is that the general practitioner has the right expertise regarding their health question. The willingness to relocate care from the general practitioner to other healthcare providers or to self-care is also present. One of the problems, however, is that citizens often do not know to which healthcare provider they should go or what they should do to increase self-care., Conclusion: From a citizens' perspective, relocating care is an acceptable solution for keeping healthcare sustainable in the future, provided that certain conditions are met., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Damen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Published: 2024
Full Text: View/download PDF

39. Predicting unplanned admissions to hospital in older adults using routinely recorded general practice data: development and validation of a prediction model.

Author: Klunder JH, Heymans MW, van der Heide I, Verheij RA, Maarsingh OR, van Hout HP, and Joling KJ
Subjects: Humans, Aged, Female, Male, Retrospective Studies, Risk Assessment, Aged, 80 and over, Electronic Health Records, Independent Living, Routinely Collected Health Data, Risk Factors, Patient Admission statistics & numerical data, General Practice, Hospitalization statistics & numerical data
Abstract: Background: Unplanned admissions to hospital represent a hazardous event for older people. Timely identification of high-risk individuals using a prediction tool may facilitate preventive interventions., Aim: To develop and validate an easy-to-use prediction model for unplanned admissions to hospital in community-dwelling older adults using readily available data to allow rapid bedside assessment by GPs., Design and Setting: This was a retrospective study using the general practice electronic health records of 243 324 community-dwelling adults aged ≥65 years linked with national administrative data to predict unplanned admissions to hospital within 6 months., Method: The dataset was geographically split into a development ( n = 142 791/243 324, 58.7%) and validation ( n = 100 533/243 324, 41.3%) sample to predict unplanned admissions to hospital within 6 months. The performance of three different models was evaluated with increasingly smaller selections of candidate predictors (optimal, readily available, and easy-to-use models). Logistic regression was used with backward selection for model development. The models were validated internally and externally. Predictive performance was assessed by area under the curve (AUC) and calibration plots., Results: In both samples, 7.6% (development cohort: n = 10 839/142 791, validation cohort: n = 7675/100 533) had ≥1 unplanned hospital admission within 6 months. The discriminative ability of the three models was comparable and remained stable after geographic validation. The easy-to-use model included age, sex, prior admissions to hospital, pulmonary emphysema, heart failure, and polypharmacy. Its discriminative ability after validation was AUC 0.72 (95% confidence interval = 0.71 to 0.72). Calibration plots showed good calibration., Conclusion: The models showed satisfactory predictive ability. Reducing the number of predictors and geographic validation did not have an impact on predictive performance, demonstrating the robustness of the model. An easy-to-use tool has been developed in this study that may assist GPs in decision making and with targeted preventive interventions., (© The Authors.)
Published: 2024
Full Text: View/download PDF

40. Development of the Patient-Reported Indicator Surveys (PaRIS) conceptual framework to monitor and improve the performance of primary care for people living with chronic conditions.

Author: Valderas JM, Porter I, Martin-Delgado J, Rijken M, de Jong J, Groene O, Bloemeke-Cammin J, Sunol R, Williams R, Ballester M, de Bienassis K, Kendir C, Guanais F, de Boer D, and van den Berg M
Abstract: BackgroundThe Organisation for Economic Co-operation and Development (OECD) Patient-Reported Indicator Surveys (PaRIS) initiative aims to support countries in improving care for people living with chronic conditions by collecting information on how people experience the quality and performance of primary and (generalist) ambulatory care services. This paper presents the development of the conceptual framework that underpins the rationale for and the instrumentation of the PaRIS survey., Methods: The guidance of an international expert taskforce and the OECD Health Care Quality Indicators framework (2015) provided initial specifications for the framework. Relevant conceptual models and frameworks were then identified from searches in bibliographic databases (Medline, EMBASE and the Health Management Information Consortium). A draft framework was developed through narrative review. The final version was codeveloped following the participation of an international Patient advisory Panel, an international Technical Advisory Community and online international workshops with patient representatives., Results: 85 conceptual models and frameworks were identified through searches. The final framework maps relationships between the following domains (and subdomains): patient-reported outcomes (symptoms, functioning, self-reported health status, health-related quality of life); patient-reported experiences of care (access, comprehensiveness, continuity, coordination, patient safety, person centeredness, self-management support, trust, overall perceived quality of care); health and care capabilities; health behaviours (physical activity, diet, tobacco and alcohol consumption), sociodemographic characteristics and self-reported chronic conditions; delivery system characteristics (clinic, main healthcare professional); health system, policy and context., Discussion: The PaRIS conceptual framework has been developed through a systematic, accountable and inclusive process. It serves as the basis for the development of the indicators and survey instruments as well as for the generation of specific hypotheses to guide the analysis and interpretation of the findings., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Published: 2024
Full Text: View/download PDF

41. One-year evaluation of people recovering from COVID-19 receiving allied primary healthcare: A nationwide prospective cohort study.

Author: Gerards MHG, Slotegraaf AI, Verburg AC, Kruizenga HM, Cup EHC, Kalf JG, Lenssen AF, Meijer WM, Ben ÂJ, van Dongen JM, de van der Schueren MAE, Graff MJL, Akkermans RP, van der Wees PJ, and Hoogeboom TJ
Abstract: Background: A Dutch nationwide prospective cohort study was initiated to investigate recovery trajectories of people recovering from coronavirus disease 2019 (COVID-19) and costs of treatment by primary care allied health professionals., Objectives: The study described recovery trajectories over a period of 12 months and associated baseline characteristics of participants recovering from COVID-19 who visited a primary care allied health professional. It also aimed to provide insight into the associated healthcare and societal costs., Methods: Participants completed participant-reported standardized outcomes on participation, health-related quality of life, fatigue, physical functioning, and costs at baseline (ie, start of the treatment), 3, 6, 9 and 12 months., Results: A total of 1451 participants (64 % women, 76 % mild/moderate severity) with a mean (SD) age of 49 (12) years were included. Linear mixed models showed significant and clinically relevant improvements over time in all outcome measures between baseline and 12 months. Between 6 and 12 months, we found significant but not clinically relevant improvements in most outcome measures. Having a worse baseline score was the only baseline factor that was consistently associated with greater improvement over time on that outcome. Total allied healthcare costs (mean €1921; SEM €48) made up about 3% of total societal costs (mean €64,584; SEM €3149) for the average participant in the cohort., Conclusions: The health status of participants recovering from COVID-19 who visited an allied health professional improved significantly over a 12-month follow-up period, but nearly the improvement occurred between baseline and 6 months. Most participants still reported severe impairments in their daily lives, and generated substantial societal costs. These issues, combined with the fact that baseline characteristics explained little of the variance in recovery over time, underscore the importance of continued attention for the management of people recovering from COVID-19., Trial Registration: clinicaltrials.gov (NCT04735744)., Competing Interests: Declaration of competing interest None., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

42. Practice variation in home care nursing: mapping potential explanations through a scoping review of the literature.

Author: Brabers AEM, Meijer MAM, Groenewegen PP, Bleijenberg N, Zwakhalen S, and de Jong JD
Abstract: Needs assessment is the starting point of good home care as it determines which care is necessary, based on the needs of patients, their personal situation, and social context. There are indications that practice variation in needs assessment exists among home care nurses. However, little is known about potential explanations for this variation. Therefore, we explored potential explanations for practice variation in other areas and examined whether these explanations can be applied to explain variation in needs assessment in home care nursing. We conducted a scoping review of the literature on practice variation in (1) needs assessment in home care nursing, (2) home care nursing in general, and (3) medical care in general, with searches in PubMed and CINAHL. We assessed over 6,000 references. Ultimately, 386 studies were included. Explanations for practice variation were grouped into micro, meso and macro level. This scoping review provided insight into a wide variety of variables that might play a role in explaining practice variation in (needs assessment in) home care nursing, such as availability of guidelines, organisational culture, team norms, resources, and preferences of patients. However, the small literature on needs assessment by home care nurses devoted more attention to patients and their social context, compared to the literature on practice variation in general. We discuss how and to what extent these variables could relate to practice variation in (needs assessment in) home care nursing. Future research should empirically examine the role of these variables in explaining the observed practice variation., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

43. Validation of the Persistent Somatic Symptom Stigma scale for Healthcare Professionals (PSSS-HCP).

Author: McGhie-Fraser B, Ballering A, Lucassen P, McLoughlin C, Brouwers E, Stone J, Olde Hartman T, and van Dulmen S
Abstract: Objective: Persistent somatic symptoms (PSS) describe recurrent or continuously occurring symptoms such as fatigue, dizziness, or pain that have persisted for at least several months. These include single symptoms such as chronic pain, combinations of symptoms, or functional disorders such as fibromyalgia or irritable bowel syndrome. While many studies have explored stigmatisation by healthcare professionals towards people with PSS, there is a lack of validated measurement instruments. We recently developed a stigma scale, the Persistent Somatic Symptom Stigma scale for Healthcare Professionals (PSSS-HCP). The aim of this study is to evaluate the measurement properties (validity and reliability) and factor structure of the PSSS-HCP., Study Design and Setting: The PSSS-HCP was tested with 121 healthcare professionals across the United Kingdom to evaluate its measurement properties. Analysis of the factor structure was conducted using principal component analysis. We calculated Cronbach's alpha to determine the internal consistency of each (sub)scale. Test re-test reliability was conducted with a sub-sample of participants with a two-week interval. We evaluated convergent validity by testing the association between the PSSS-HCP and the Medical Condition Regard Scale (MCRS) and the influence of social desirability using the short form of the Marlowe Crowne Social Desirability Scale (MCSDS)., Results: The PSSS-HCP showed sufficient internal consistency (Cronbach's alpha = 0.84) and sufficient test-retest reliability, intraclass correlation = 0.97 (95% CI 0.94 to 0.99, p<0.001). Convergent validity was sufficient between the PSSS-HCP and the MCRS, and no relationship was found between the PSSS-HCP and the MCSDS. A three factor structure was identified (othering, uneasiness in interaction, non-disclosure) which accounted for 60.5% of the variance using 13 of the 19 tested items., Conclusion: The PSSS-HCP can be used to measure PSS stigmatisation by healthcare professionals. The PSSS-HCP has demonstrated sufficient internal consistency, test-retest reliability, convergent validity and minimal influence of social desirability bias. The PSSS-HCP has demonstrated potential to measure important aspects of stigma and provide a foundation for stigma reduction intervention evaluation., (Copyright © 2024. Published by Elsevier Inc.)
Published: 2024
Full Text: View/download PDF

44. Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review.

Author: Hansen CME, Breukelman AJ, van den Bemt PMLA, Zwitserloot AM, van Dijk L, and van Boven JFM
Subjects: Humans, Treatment Outcome, Chloride Channel Agonists therapeutic use, Quinolones therapeutic use, Female, Male, Adolescent, Young Adult, Drug Combinations, Adult, Child, Aminophenols therapeutic use, Aminopyridines therapeutic use, Lung drug effects, Lung physiopathology, Child, Preschool, Benzodioxoles, Cystic Fibrosis drug therapy, Cystic Fibrosis physiopathology, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Medication Adherence
Abstract: Background: In the last decade, a fundamental shift in the treatment of cystic fibrosis (CF) took place due to the introduction of CF transmembrane conductance regulator (CFTR) modulators. Adequate medication adherence is a prerequisite for their effectiveness, but little is known about adherence to CFTR modulators. We aimed to assess the extent of medication adherence to CFTR modulators in patients with CF and assess which characteristics are associated with adherence., Methods: A systematic review following PRISMA guidelines was performed. Studies needed to report adherence to CFTR modulators. Main outcomes were: 1) level of medication adherence and 2) associations of demographic and/or clinical characteristics with adherence., Results: In total, 4082 articles were screened and 21 full-text papers were assessed for eligibility. Ultimately, seven studies were included. Most studies were retrospective and focused on adherence to ivacaftor or lumacaftor-ivacaftor with only one focusing on elexacaftor-tezacaftor-ivacaftor. The majority used pharmacy refill data with adherence determined with the proportion of days covered (PDC) or the medication possession ratio (MPR). One study additionally used electronic monitoring and patient self-reported adherence. Adherence was 0.62-0.99 based on pharmacy data (PDC or MPR), 61% via electronic monitoring and 100% via self-report. Age <18 years appeared to be associated with good adherence, as was a higher lung function., Conclusions: Despite the wide variety of adherence methods used, adherence to CFTR modulators is suboptimal, based on objective measures such as pharmacy refill data or electronic monitoring. CFTR modulator adherence measurement and definitions requires more standardisation with a preference for objective and granular methods., Competing Interests: Conflict of interest: C.M.E. Hansen received a travel grant for the ECFS in 2023 (money paid to institution). A.M. Zwitserloot reports grants from Vertex Pharmaceuticals (IIS-2018-107391) and participation in an advisory board meeting for Sanofi (money paid to institution). J.F.M. van Boven reports consulting and advisory grants from Vertex (money paid to institution). The other authors declare that they have no know competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright ©The authors 2024.)
Published: 2024
Full Text: View/download PDF

45. Comparing Guidelines to Daily Practice When Screening Older Patients for the Risk of Functional Decline in Hospitals: Outcomes of a Functional Resonance Analysis Method (FRAM) Study.

Author: Meulman MD, Merten H, van Munster B, and Wagner C
Abstract: Objectives: Dutch hospitals are required to screen older patients for functional decline using 4 indicators: malnutrition, delirium, physical impairment, and falls, to recognize frail older patients promptly. The Functional Resonance Analysis Method was employed to deepen the understanding of work according to the protocols (work-as-imagined [WAI]) in contrast to the realities of daily practice (work-as-done [WAD])., Methods: Data have been collected from 3 hospitals (2 tertiary and 1 general) and 4 different wards: an internal medicine ward, surgical ward, neurology ward, and a trauma geriatric ward. WAI models were based on national guidelines and hospital protocols. Data on WAD were collected through semistructured interviews with involved nurses (n = 30)., Results: Hospital protocols were more extensive than national guidelines for all screening indicators. Additional activities mainly comprised specific preventive interventions or follow-up assessments after adequate measurements. Key barriers identified to work according to protocols included time constraints, ambiguity regarding task ownership, nurses' perceived limitations in applying their clinical expertise due to time constraints, insufficient understanding of freedom-restricted interventions, and the inadequacy of the Delirium Observation Scale Score in patients with neurological and cognitive problems. Performance variability stemmed from timing issues, frequently attributable to time constraints., Conclusions: The most common reasons for deviating from the protocol are related to time constraints, lack of knowledge, and/or patient-related factors. Also, collaboration among relevant disciplines appears important to ensure good health outcomes. Future research endeavors could shed a light on the follow-up procedures of the screening process and roles of other disciplines, such as physiotherapists., Competing Interests: The authors disclose no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

46. Disease Burden of RSV Infections and Bronchiolitis in Young Children (< 5 Years) in Primary Care and Emergency Departments: A Systematic Literature Review.

Author: Heemskerk S, van Heuvel L, Asey T, Bangert M, Kramer R, Paget J, and van Summeren J
Subjects: Humans, Infant, Child, Preschool, Incidence, Respiratory Syncytial Virus, Human isolation & purification, Cost of Illness, Infant, Newborn, Respiratory Syncytial Virus Infections epidemiology, Emergency Service, Hospital statistics & numerical data, Primary Health Care statistics & numerical data, Bronchiolitis epidemiology, Bronchiolitis virology
Abstract: Respiratory syncytial virus (RSV) is the most common cause of acute respiratory infections in young children. Limited data are available on RSV disease burden in primary care and emergency departments (EDs). This review synthesizes the evidence on population-based incidence rates of RSV infections in young children (< 5 years) in primary care and EDs. A systematic literature review was performed in PubMed and Embase. Studies reporting yearly population-based RSV incidence rates in primary care and EDs were included. A total of 4244 records were screened and 32 studies were included, conducted between 1993 and 2019. Studies were mainly performed in high-income countries (n = 27), with 15 studies in North America and 10 studies in Europe. There was significant variability in study methodology and setting among studies, resulting in considerable variability in reported incidence rates. Incidence rates were higher in primary care-ranging from 0.8 to 330 (median = 109) per 1000 population-compared to EDs (7.5-144.0, median = 48). The highest incidence rates were reported in infants. Additionally, incidence rates were higher in high-income countries and in studies using laboratory-confirmed RSV cases compared to studies using bronchiolitis ICD-codes (non-laboratory confirmed). Our study found that a substantial number of children under 5 years of age attend primary care settings and EDs, every year for RSV infections. Due to the considerable heterogeneity in study methodology, it was impossible to draw definitive conclusions regarding factors explaining differences in reported incidence rates. Additionally, more studies in low- and middle-income countries are recommended., (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

47. The prediagnostic general practitioner care of sarcoma patients: A real-world data study.

Author: Holthuis EI, van der Graaf WTA, Drabbe C, van Houdt WJ, Schrage YM, Hartman TCO, Uijen AA, Bos I, Heins M, and Husson O
Subjects: Humans, Male, Female, Middle Aged, Netherlands epidemiology, Adult, Case-Control Studies, Aged, Registries, Bone Neoplasms diagnosis, Bone Neoplasms therapy, Referral and Consultation statistics & numerical data, Follow-Up Studies, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms therapy, General Practice, Prognosis, Young Adult, Sarcoma diagnosis, Sarcoma therapy, General Practitioners
Abstract: Background: Limited understanding exists regarding early sarcoma symptoms presented during general practitioner (GP) consultations. The study explores GP visit patterns and recorded diagnoses in the 12 months preceding sarcoma diagnosis., Methods: Sarcoma cases diagnosed from 2010 to 2020 were identified through the Netherlands Cancer Registry alongside general practice data. Sarcoma cases were age and gender matched to cancer-free controls (2:1 or 1:1 ratio)., Results: A total of 787 individuals with soft-tissue sarcoma (STS) and 188 individuals with bone sarcoma (BS) were identified. There was a significant difference in monthly GP contacts from 4 months to the last month before STS diagnosis, and 2 months before BS diagnosis between cases and controls. Most prevalent diagnoses recorded by the GP for STS cases included musculoskeletal neoplasm (26.6%), uncomplicated hypertension (15.6%), and cystitis/other urinary infections (12.2%). For BS cases, musculoskeletal neoplasm (42.8%), knee symptoms/complaints (9.7%), and shoulder symptoms/complaints (9.7%) were most frequent., Conclusions and Discussion: A significant difference in GP contacts between cases and controls preceding sarcoma diagnosis. STS cases were predominantly diagnosed with nonspecific symptoms, whereas BS cases with diagnoses more suggestive of BS. Better understanding of the prediagnostic trajectory could aid GPs in early identification of sarcoma., (© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.)
Published: 2024
Full Text: View/download PDF

48. Personal protective equipment for healthcare workers during COVID-19: Developing and applying a questionnaire and assessing associations between infection rates and shortages across 19 countries.

Author: Kroneman M, Williams GA, Winkelmann J, Spreeuwenberg P, Davidovics K, and Groenewegen PP
Subjects: Humans, Surveys and Questionnaires, Europe epidemiology, Infectious Disease Transmission, Patient-to-Professional prevention & control, Infection Control methods, COVID-19 epidemiology, COVID-19 prevention & control, Personal Protective Equipment supply & distribution, Health Personnel, SARS-CoV-2
Abstract: This study aimed to assess the preparedness of European countries regarding personal protective equipment (PPE) for health and care workers (HCWs), the COVID-19 infection rates of HCWs compared to the general working age population, and the association between these. We developed a PPE-preparedness scale based on responses to a questionnaire from experts in the Health Systems and Policy Monitor network, with a response rate of 19 out of 31 countries. COVID-19 infection data were retrieved form the European center for Disease Prevention and Control. Shortages of PPE were found in most countries, in particular in home care and long-term care. HCW infection rates, compared to the general population, varied strongly between countries, influenced by different testing regimes. We found no relationships between HCW infection rates, PPE preparedness and shortages of PPE. Improved surveillance in the population as well as for HCWS are needed to be able to better assess these relationships., (Copyright © 2024. Published by Elsevier B.V.)
Published: 2024
Full Text: View/download PDF

49. Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases.

Author: Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B, Del Riccio M, and Paget J
Subjects: Humans, Global Health, COVID-19 epidemiology, COVID-19 prevention & control, Databases, Factual, SARS-CoV-2, Pandemics, Influenza, Human epidemiology, Influenza, Human virology, Influenza B virus genetics, Influenza B virus isolation & purification, Public Health
Abstract: Early after the start of the COVID-19 pandemic, the detection of influenza B/Yamagata cases decreased globally. Given the potential public health implications of this decline, in this Review, we systematically analysed data on influenza B/Yamagata virus circulation (for 2020-23) from multiple complementary sources of information. We identified relevant articles published in PubMed and Embase, and data from the FluNet, Global Initiative on Sharing All Influenza Data, and GenBank databases, webpages of respiratory virus surveillance systems from countries worldwide, and the Global Influenza Hospital Surveillance Network. A progressive decline of influenza B/Yamagata detections was reported across all sources, in absolute terms (total number of cases), as positivity rate, and as a proportion of influenza B detections. Sporadically reported influenza B/Yamagata cases since March, 2020 were mostly vaccine-derived, attributed to data entry errors, or have yet to be definitively confirmed. The likelihood of extinction necessitates a rapid response in terms of reassessing the composition of influenza vaccines, enhanced surveillance for B/Yamagata, and a possible change in the biosafety level when handling B/Yamagata viruses in laboratories., Competing Interests: Declaration of interests MCN received grants from the Foundation for Influenza Epidemiology, Bill & Melinda Gates Foundation, European & Developing Countries Clinical Trials Partnership (EDCTP), Sanofi, AstraZeneca, and Pfizer; received payments or honoraria (for lectures, presentations, speakers bureaus, manuscript writing, or educational events) and support for attending meetings or travel, or both, from Sanofi; and had leadership or fiduciary role from Gavi Board. An unrestricted research grant from NIVEL (the employer) and Sanofi for JP funded the work carried out in this manuscript; JP also received grants or contracts from Sanofi and the Fondation de France; and support for attending meetings or travel, or both, from WHO and Sanofi. The other authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2024
Full Text: View/download PDF

50. Recommendations on self-management interventions for adults living with obesity: COMPAR-EU project.

Author: Medina-Aedo M, Beltran J, Valli C, Canelo-Aybar C, Song Y, Ballester M, Bowman-Busato J, Christogiannis C, Grammatikopoulou MG, Groene O, Heijmans M, Hoogendorn M, Killeen SL, Kontouli KM, Mavridis D, Miñambres I, Mueller BS, Niño de Guzman E, Noordman J, Orrego C, Perestelo-Perez L, Saz-Parkinson Z, Seitidis G, Suñol R, Tsokani S, and Alonso-Coello P
Subjects: Humans, Adult, Cost-Benefit Analysis, Evidence-Based Medicine, Obesity therapy, Self-Management methods
Abstract: Self-management interventions (SMIs) may improve disease management in adults living with obesity. We formulated evidence-based recommendations for SMIs within the context of the COMPAR-EU project. The multidisciplinary panel selected critical outcomes based on the COMPAR-EU core outcome set and established decision thresholds for each outcome. Recommendations were informed by systematic reviews of effects, cost-effectiveness, and a contextual assessment. To assess the certainty of the evidence and formulate the recommendations, we used the GRADE approach guidance. Overall, SMIs were deemed to have a small impact, but the absence of harmful effects and potential cumulative benefits indicated a favourable balance of effects, despite low certainty. SMIs showed variations in structure, intensity, and resource utilisation, but overall are likely to be cost-effective. Adapting SMIs to local contexts would enhance equity, acceptability, and feasibility, considering patients' values, and availability of resources and teamwork. Consequently, the panel made conditional recommendations favouring SMIs over usual care. The rigorous and explicit recommendations demonstrated the effectiveness of SMIs for adults living with obesity. However, the gaps in the literature influenced the panel to make only conditional recommendations in favour of SMIs. Further research is needed to strengthen the evidence base and improve recommendations' certainty and applicability., (© 2024 World Obesity Federation.)
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

1,850 results on '"Netherlands Institute for Health Services Research"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources